Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
i 
  
 
 
  
 
  
Patient- Centered Models of HCV Care for People Who  Inject Drugs  
The HERO Study:  Hepatitis C Real Options  
  
 
Funding Mechanism:   PCORI  
 
Pharmaceutical Support Provided by:  Gilead 
 
 
Protocol Co -Chairs: Alain Litwin, MD, Kimberly Page, Ph.D., MPH  
 
 
Version Number:  4.0 
 
21 May 2019  
 
 
Study ID: [REMOVED]
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
ii 
 STATEMENT OF COMPLIANCE  
The study will be carried out in accordance with Good Clinical Practice (GCP) as 
required by the following:  
• United States (US) Code of Federal Regulations (CFR) applicable to clinical 
studies (45 CFR Part 46; 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 
312) 
• International Conference of H armonisation (ICH)  E6; 62 Federal Register 25691 
(1997)  
• Patient -Centered Outcomes Research Initiatives  Clinical Terms of Award  
 All key personnel (all individuals responsible for the design and conduct of this study) have completed Human Subjects Protection Training.  
 
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
iii 
 SIGNATURE PAGE  
The signatures below constitute the approval of this protocol and appendices, and 
provide the necessary assurances that this trial will be conducted according to all 
stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and ICH guidelines.  
 
 
Signed:   Date:   
 
Judith Feinberg, MD  
Co-Investigator  
West Virginia University  
Morgantown, West Virginia  
 
Signed:   Date:   
 
  Nirah Johnson, LCSW  
Co-Investigator  
New York City Department of Health and Mental Hygiene  
New York, NY   
 
Signed:   Date:   
 
Arthur Kim, M.D.  
Co-Investigator  
Massachusetts General Hospital/Harvard Medical School   
Boston, MA  
  
Signed:   Date:   
 
Alain Litwin, MD Principal Investigator  
Clemson University /Prisma Health -Upstate  
Greenville , SC  
Signed:   Date:   
 
Paula Lum, M.D., M.P.H. Co-Investigator  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
iv 
 University of California San Francisco  
San Francisco , CA 
    
Signed:   Date:   
 
 
 Shruti Mehta, Ph.D.  
Co-Investigator  
The Johns Hopkins University  
Baltimore, MD  
Signed  Brianna Norton, DO  
Co-Investigator  
Albert Einstein College of Medi cine 
New York, NY   
  Date:   
    
Signed:   Date:   
 
Kimberly Page, Ph.D., M.P.H. Co-Investigator  
University of New Mexico  
Albuquerque, NM  
 
Signed:   Date:   
 
Lynn Taylor, MD  
Co-Investigator  
University of Rhode Island  
CODAC Behavioral Health  
Providence, RI  
 
Signed:   Date:   
 
Judith Tsui, MD., M.P.H. 
Co-Investigator  
University of Washington  
Seattle, WA  
Signed:   Date:   
  
John Ward, MD  
Co-Investigator  
Centers for Disease Control and Prevention  
Atlanta, GA  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
v 
  
TABLE OF CONTENTS  
1 Key Roles  .............................................................................................................. 1 
2 Background Information and Scientific Rationale  .................................................. 5 
2.1 Background Information ............................................................................... 5 
2.2 Scientific Rationale  ...................................................................................... 9 
2.3 Potential Risks and Benefits  ........................................................................ 13 
3 Study Objectives  .................................................................................................  16 
3.1 Primary Objective  ...................................................................................... 16 
3.2 Secondary Objective 1  ................................................................................ 16 
3.3 Secondary Objective 2  ................................................................................ 16 
4 Study Design  ....................................................................................................... 18 
5 Study Population  .................................................................................................  19 
5.1 Inclusion Criteria  ........................................................................................ 20 
5.2 Exclusion Criteria  ....................................................................................... 21 
5.3 Re-Screening  ............................................................................................. 21 
5.4 Randomization ........................................................................................... 21 
5.5 Withdrawal  ................................................................................................ 22 
6 Investigational Interventions  ............................................................................... 23 
6.1 modified Directly Observed Treatment  ......................................................... 23 
6.1.1 OTP Setting  .................................................................................................. 23 
6.1.2 Community Health Center Setting .................................................................. 24 
6.2 Patient Navigation  ...................................................................................... 25 
6.3 Education and Peer Support  ......................................................................... 26 
7 Study Procedures/Evaluations  ............................................................................. 27 
7.1 Clinical Evaluations  .................................................................................... 27 
7.2 Laboratory Evaluations  ............................................................................... 27 
7.3 Non-Clinical Evaluations  ............................................................................ 28 
8 Study Schedule  .................................................................................................... 30 
8.1 Screening and Enrollment ........................................................................... 30 
8.1.1 Screening  ..................................................................................................... 30 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
vi 
 8.1.1.a.  Screening with Chart Reviews .................................................................... 30 
8.1.1.b.  Community -Based Screening  ..................................................................... 31 
8.1.2 Visit 0:  Eligibility confirmation, Consent and Enrollment Visit  ......................... 31 
8.2 Visit 1: Baseline Visit  ................................................................................. 32 
8.3 Treatment Initiation  .................................................................................... 33 
8.4 Chart Review Part 2  .................................................................................... 33 
8.5 Treatment (follow -up) visits:  ....................................................................... 34 
8.5.1  Treatment Research Visits  ............................................................................. 34 
8.5.1.a  Visit 2: week 4 of treatment, ± 7 days  .......................................................... 34 
8.5.1.b  Visit 3: week 8 of treatment, ± 7 days  .......................................................... 34 
8.5.1.c  Visit 4: week 12 of treatment, ± 7 days  ........................................................ 35 
8.6 Post-treatment (follow -up) visits  .................................................................. 36 
8.6.1 Visit 5: week 24, ±14 days  ............................................................................. 36 
8.6.2 Visit 6: week 36, ± 14 days  ............................................................................ 37 
8.46.3 Visit 7: week 48, ± 14 days  .......................................................................... 37 
8.6.4 Visit 8: week 60, ± 14 days  ............................................................................ 38 
8.6.5 Visit 9: week 72, ± 14 days  ............................................................................ 38 
8.6.6 Visit 10: week 84, ± 14 days  .......................................................................... 39 
8.6.7 Visit 11: week 96, ± 14 days  .......................................................................... 39 
8.6.8 Visit 12: week 108, ± 14 days  ......................................................................... 39 
8.6.9 Visit 13: week 120, ±  14 days  ......................................................................... 40 
8.6.10 Visit 14: week 132, ± 14 days  ....................................................................... 41 
8.46.11 Visit 15: week 144, ± 14 days  ..................................................................... 41 
8.6.12  Visit 16: week 156, ± 14 days  ...................................................................... 41 
8.6.13  Visit 17: week 168, ± 14 days (Exit interview)  .............................................. 42 
8.7 Unscheduled Visits  ..................................................................................... 43 
8.8 Patient Navigator Encounters  ....................................................................... 43 
8.7.1 Initial Visit (Required)  ................................................................................... 43 
8.7.2  Treatment Readiness Encounter (Required)  .................................................... 44 
8.7.3  Treatment Adherence Encounter (3 days post treatment initiation -  Required)  .... 44 
8.7.4  Treatment Period Encounters (Weeks 1 -11) (Recommended)  ........................... 44 
8.7.5  After Treatment Encounter (Week 12 of treatment) (Required)  ......................... 45 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
vii 
 8.9 mDOT Visits  ............................................................................................. 45 
9 Safety Reporting and Safety Assessment Monitoring ............................................ 46 
9.1 Data and Safety  Monitoring Plan. .................................................................  46 
9.2 Data monitoring  plan .................................................................................. 46 
9.3 Data Confidentiality  ................................................................................... 46 
9.4 Serious Adverse Events  ............................................................................... 46 
10 Stakeholder Engagement  ..................................................................................... 48 
11 Statistical Considerations  .................................................................................... 49 
11.1  Independent Parallel Analysis  ...................................................................... 49 
11.2  Definition of Study Subjects  ........................................................................ 49 
11.3  Study Hypotheses  ....................................................................................... 49 
11.4  Sample Size Determination  ......................................................................... 50 
11.5  Primary  Analytic  Principle  .......................................................................... 50 
11.6  Preliminary  Data Analysis  ........................................................................... 50 
11.7  Missing  data analysis  .................................................................................. 51 
11.8  Heterogeneity  of mDOT  or PN effects  .......................................................... 52 
11.9  Mediated m DOT  or PN effects  ..................................................................... 52 
11.10  Analytic  plan for Primary and Secondary outcomes : SVR, Treatment initiation 
rate, Adherence rate, and Treatment completion rate ........................................................ 52 
11.11  Analytic plan  for Resistance and Reinfection Rates  ........................................ 55 
11.12  Analytic  plan  for Aim 3............................................................................... 56 
11.12.1  Patient  Navigator  (PN) Stakeholder  Qualitative Study.  .................................  56 
11.12.2  The Patient Stakeholder Qualitative Study. .................................................. 56 
11.12.3  Quantitative Analysis  ................................................................................ 57 
12 Data Handling/Record Keeping/Source Documents  .............................................. 59 
12.1  Source Documents and Access to Source Documents  ..................................... 59 
12.2  Data Management Responsibilities  ............................................................... 59 
12.3  Data Capture Methods  ................................................................................ 60 
12.4  Types of Data  ............................................................................................ 60 
12.5  Timing/Reports  .......................................................................................... 60 
12.6  Study Records Retention ............................................................................. 60 
13 Quality Assurance  ............................................................................................... 62 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
viii 
 14 Ethics/Protection of Human Subjects  ................................................................... 63 
14.1  Ethical Standard/Declaration of Helsinki ...................................................... 63 
14.2  Institutional Review Board  .......................................................................... 63 
14.3  Informed Consent Process  ........................................................................... 63 
14.4  Subject Confidentiality  ............................................................................... 66 
15 Protocol Conduct  ................................................................................................ 68 
15.1  Record Confidentiality ................................................................................ 68 
15.2  Data Collection, Handling, Source Documents  .............................................. 68 
15.3  Protocol Deviations  .................................................................................... 69 
15.4  Recruitment and Retention of Study Subjects  ................................................ 69 
15.5  Study Subject Reimbursement  ..................................................................... 70 
16 Publication Policy  ................................................................................................ 71 
17 References  ........................................................................................................... 72 
Appendix One: Patient Navigator Tasks  ......................................................................... 80 
Appendix 2: Check Hep C Patient Navigation Program – Workflow for Project HERO  .. 82 
Appendix Three:  Study Visit Table  ................................................................................ 83 
Appendix Four: Implementation Study  .......................................................................... 86 
 
 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
ix 
 LIST OF ABBREVIATIONS  
Ab Antibody  
AASLD  American Association for the Study of Liver Diseases  
ACTG  AIDS Clinical Trials Group  
AE Adverse Event/Adverse Experience  
AIDS  Acquired Immune Deficiency Syndrome  
ALT Alanine Aminotransferase  
APRI  AST to Platelet Ratio Index  
ASI Addiction Severity Index  
AST Aspartate Aminotransferase  
AUDIT  Alcohol Use Disorders Identification Test  
CHC  Community  Health Center  
CBO  Community -Based Organization  
CD4 Cluster of Differentiation 4  
CDC  Centers for Disease Control and Prevention  
CI Confidence Interval  
CITI Collaborative Institutional Training Initiative  
CFR Code of Federal Regulations  
Co-I Co-Investigator  
CRC  Clinical Research Center  
CRF Case Report Form  
CT Computed Tomography   
DAA Direct -acting Antiviral Agent  
DOH  Department of Health  
DOT  Directly Observed Therapy  
DSM  Data and Safety Monitoring  
EASL  European Association for the Study of the Liver  
eCRF  Electronic Case Report Form  
eDOT  Electronic Directly Observed Therapy  
EDTA  Ethylenediaminetetraacetic Acid  
ETR End of Treatment Response  
FDA Food and Drug Administration, DHHS  
FDC Fixed Dose Combination  
FIB Fibrosis  
FQHC  Federally Qualified Health Center  
FWA  Federalwide Assurance  
GAD  Generalized Anxiety Disorder  
GCP  Good Clinical Practice  
HAART  Highly Active Anti -Retroviral Therapy  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
x 
 HBsAg  Hepatitis B Surface Antigen  
HBV Hepatitis B Virus  
HCC  Hepatocellular Carcinoma  
HCV  Hepatitis C Virus  
HERO  Hepatitis C Real Options  
HgB Hemoglobin  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HRC  Human Rights Campaign  
HU Harvard University  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ID Identification  
IDSA  Infectious Diseases Society of America  
IEC Independent or Institutional Ethics Committee  
IFN Interferon  
IMB Information -Motivation -Behavioral  
INHSU  International Network of Hepatitis in Substance Users  
IOM Institute of Medicine  
IRB Institutional Review Board  
IU International Units  
JHU The Johns Hopkins University  
LSAB  Local Stakeholder Advisory Board  
MARS  Medication Assisted Recovery Services  
mDOT  Modified Directly Observed Therapy  
mg Milligram  
mL Milliliter  
MMC  Montefiore Medical Center  
MOP  Manual of Procedures  
MRI Magnetic Resonance Imaging  
MSM  Men who have Sex with Men  
N Number (Typically Refers to Subjects)  
NAMA  National Alliance for Medication Assisted Recovery  
NATAP  National AIDS Treatment Advocacy Project  
NIH National Institutes of Health, DHHS  
NSAB  National Stakeholder Advisory Board  
NVHR  National Viral Hepatitis Roundtable  
NYCDOH  New York City Department of Health  
NYCDOHMH  New York City Department of Health and Mental Hygiene  
OAT Opiate Agonist Treatment  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
xi 
 OHRP  Office for Human Research Protections  
OR Odds Ratio  
OTP Opioid Treatment Program  
PCORI  Patient -Centered Outcomes Research Institute  
PD Protocol Deviation  
PHQ  Patient Health Questionnaire  
PI Principal Investigator  
PN Patient Navigator  
POC  Point of Care  
PWID  People Who Inject Drugs  
PY Person -Years  
RA Research Assistant  
RAV Resistance -associated Variant  
RCT Randomized Control Trial  
REDCap  Research Electronic Data Capture  
RNA  Ribonucleic Acid  
SAE Serious Adverse Event/Serious Adverse Experience  
SAS Statistical Analysis System  
SD Standard Deviation  
SDCC  Statistical and Data Coordinating Center  
SMS  Short Message Service  
SOP  Standard Operating Procedure  
SVR Sustained Virologic Response  
TAG The Advocacy Group  
TAU Treatment as Usual  
UCSF  University of California San Francisco  
UNM HSC  University of New Mexico Health Science Center  
URI University of Rhode Island  
US United States  
UT Urine Toxicology  
UW University of Washington  
VAS Visual Analogue Scale  
VL Viral Load  
WHO  World Health Organization  
WVU  West Virginia University  
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
xii 
 LIST OF TABLES  
Table 1: HCV -infected Patients at OTPs and Community Health Centers  .................... 19 
Table 2: Demographic, Clinical, and Psychosocial Characteristics of HCV -infected 
Patients  ............................................................................................................ 20 
Table 3: Study Visit Table  ............................................................................................. 83 
 
LIST OF FIGURES  
Figure 1:  Schematic of Study Design  ........................................................................... xiii 
Figure 2: Barriers to Treatment  ....................................................................................... 7 
Figure 3: FQHCs in the US  ........................................................................................... 10 
Figure 4: HCV Care Cascade  ........................................................................................ 10 
Figure 5: HCV Care Cascade  ........................................................................................ 10 
 
 
   
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
xiii 
  
 
 
Total N=1000±32  
SCREENING  
OTP 
 (N=UP TO 500±16)  
CHC  
 (N=UP TO 500±16)  
ARM B  
PN 
N~250  
ARM A  
MDOT  
N~250  
VISIT 0: CONSENT, ENROLLMENT 
AND RANDOMIZATION   
SCREENING  
ARM B  
PN 
N~250  
ARM A  
MDOT  
N~250  
VISIT 0: CONSENT, ENROLLMENT 
AND RANDOMIZATION  
VISITS 5, 6, 7, 8, 9, 10, 11, 12 , 13, 14, 15, 
16 AND 17:  POST -TREATMENT  
ARM B  
PN 
N=150±4  
ARM A  
MDOT  
N=150±4  
RESEARCH VISITS 2, 3, AND 4:  
During Treatment  
VISIT 1: BASELINE  
ARM B  
4+ PN VISITS 
OVER 12 
WEEKS  
ARM A  
3-7 MDOT 
VISITS/WEEK 
FOR 12 WEEKS  
INTERVENTION VISITS DURING 
TREATMENT  
VISITS 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 
16 AND 17:  POST -TREATMENT  
ARM B  
PN 
N=150±4  
ARM A  
MDOT  
N=150±4  
RESEARCH VISITS 2, 3, AND 4:  
During Treatment  
VISIT 1: BASELINE  
ARM B  
4+ PN VISITS 
OVER 12 
WEEKS  
ARM A  
3-7 MDOT 
VISITS/WEEK 
FOR 12 WEEKS  
INTERVENTION VISITS DURING 
TREATMENT  Figure 1:  Schematic of Study Design  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
xiv 
 PROTOCOL SUMMARY  
 
Title:  Patient -Centered Models of HCV Care for People Who 
Inject Drugs  
 
Design:  
  
Two arm study  evaluating modified directly observed 
therapy  (mDOT ) versus patient navigator (PN) to deliver 
HCV treatment to PWID in two health settings : (1) opioid 
treatment program (OTP), (2) community health center 
(CHC)  
-Sites in eight cities  (16 programs)  
 
 Total number of subjects: Up to 1000 subjects will be 
enrolled and randomized with an expected 600 participants 
initiating treatment . 
 
Participants:  600 subjects  on treatment  
Arm A: (1) OTP , N=150; (2) C HC, N=150  
Arm B: (1) OTP, N=150; (2) CHC, N=150  
 
Population:  
 
 
Number of Sites:  Adults of any gender  with current  Hepatitis C Virus (HCV)  
infection, people with recent active injection drug use , 18 – 
70 years old.  
 
Eight Sites (Montefiore Medical Center, New York;  West 
Virginia University , Morgantown; University of Washington, 
Seattle; University of Rhode Island, Providence; University 
of California San Francisco; The Johns Hopkins University, Baltimore; University of New Mexico, Albuquerque)  
 
Study Duration:  Approximately 6 years  
 
Subject Participation 
Duration:  Up to 180 weeks:  up to 12 weeks of pre -treatment 
evaluation, 12 weeks of treatment, 12 weeks of follow -up 
to determine S ustained Virologic Response (SVR) 12, and 
144 weeks of follow -up to determine long- term SVR and 
reinfection  
 
Description of Intervention:  Participants will be randomized to one of two treatment 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
xv 
 model arms:  A : mDOT or B : PN, at one of two clinical 
sites:  1) opioid treatment program (OTP)  or (2) community 
health center  (CHC) setting . 
 
Objectives : 1. To determine  whether  SVR-12 rates are higher 
among those randomized to mDOT compared to 
those randomized to PN, among P eople Who Inject 
Drugs (PWID) treated at opioid treatment program 
(OTP)  and community health centers  (CHC) . 
 
2. We will also examine the following outcomes overall, 
and by randomization arm ( mDOT vs. PN) : 
(1) HCV treatment initiation   
(2) Adherence  
(3) Treatment c ompletion  
(4) Drug resistance  
(5) HCV reinfection  
 
3. To examine factors associated with key study outcomes (treatment initiation, adherence, SVR, drug resistance and HCV reinfection) using quantitative and qualitative methods.  
 
 
 
Estimated Date of 
Completion:  2022 
 
  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
1 
 1 Key Roles 
 
Clemson University/Prisma Health -Upstate  
Alain Litwin, MD, MPH  Principal Investigator ; Protocol Co -Chair  
 Department of Medicine701 Grove Road  
Greenville , SC 29605  
Cell: 1 -845-800-2885  
Fax: 864-455-5008  
Alain.L itwin@ prismahealth .org 
Moonseong Heo, PhD  Co-investigator and Statistician  
  
Irene Pericot -Valverde  Project Director  
  
Montefiore Medical Center and Albert Einstein College of Medicine  
Brianna Norton  Site Investigator  
305 East 161st, Room 7  
Bronx, NY 10451  
Office: 1 -718-579-2500  
Fax: 1 -718-579-2599  
bnorton@montefiore.org  
  
Julia Arnsten, MD, MPH  Co-Investigator  
  
Diane McKee, MD  Co-Investigator  
  
Alison Karasz, PhD  Co-investigator  
  
Paul Meissner, MPH  Co-Investigator  
  
Paula McKinley, PhD  Co-Investigator and National Project Director  
  
Linda Agyemang, MPH  Local Project Director  
  
Kiara Lora  Research Coordinator  
University of Rhode Island  
Lynn E. Taylor, MD  Site Investigator  
 University of Rhode Island  
80 Washington Street  
Providence, RI 0290 3 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
2 
 Office phone 401. 277.5001  
CODAC Behavioral Health  
Mobile 401 556 6603  
email LTaylor@uri.edu  
  
Aurielle Thomas  Project Director  
  
Harvard Medical School and Massachusetts General Hospital  
Arthur Kim, MD  Site Investigator  
 Massachusetts General Hospital  
55 Fruit Street/Cox 5  
Boston, MA  02130  
Office phone 617- 724-3230  
Office fax 617 -726-5411  
Mobile 617- 676-7846  
Email akim1@mgh.harvard.edu  
Jillian Roche, BA  Project Director  
West Virginia University  
Judith Feinberg, MD  Site Investigator  
 Department of Behavioral Medicine & Psychiatry  
and Department of Medicine  
930 Chestnut Ridge Rd 
Morgantown, WV 26505 USA  
Office: +1 (304) 293- 5861  
Mobile: +1 (513) 722- 5587  
Email: Judith.feinberg@hsc.wvu.edu  
 
  
Samuel Wilkinson,  Project Director  
  
University of New Mexico (UNM)  
Kimberly Page, Ph.D., 
M.P.H. Site Investigator ; Protocol Co -Chair  
Department of Internal Medicine  
University of New Mexico Health Sciences Center  
MSC10 5550  
1 University of New Mexico  
Albuquerque, NM 87131- 0001 USA 
Phone: +1 (505) 272- 2520 (office)  
Mobile:+1 (415) 350 -0625  
Email:  Pagek@salud.unm.edu  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
3 
   
Karla Thornton, M.D., 
M.P.H. 
 Physician Investigator   
University of New Mexico Health Sciences Center  
Albuquerque, NM 87131- 0001 USA  
Phone: +1 (505) 272- 6335 (office)  
Mobile: +1  (505) 504- 8045  
Email: kthornton@salud.unm.edu   
  
Katherine Wagner  Project Director  
  
University  of Washington School of Medicine  
Judith Tsui, MD  Site Investigator  
University of Washington School of Medicine  
Department of Medicine 
325 9th Ave, Box 359780  
Seattle, WA  98104  
Phone : +1 (206) 744- 1835  
Fax : +1 (206) 744- 9917  
Email : tsuij@uw.edu  
  
Kendra Blalock  Project Director  
  
University of California, San Francisco (UCSF)  
Paula Lum, M.D., M.P.H.  Site Investigator  
 University of California, San Francisco  
995 Potrero Ave, SFGH, Bldg 80, Ward 84  
San Francisco, CA 94110 USA  
Phone: +1 (415) 476- 4082, ext 411  
Pager: +1 (415) 443- 3407  
Email: plum@php.ucsf.edu    
  
Annie Luetkemeyer, MD  Significant Contributor  
  
Ellen Stein  Co-investigator  
  
The Johns Hopkins University, Baltimore (JHU)  
Shruti Mehta, PhD  Site Investigator  
Bloomberg School of Public H ealth  
Department of E pidemiology   
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
4 
 615 N Wolfe St . E6546   
Baltimore, MD 21205  
Phone: (443) 287- 3837  
Email:  smehta@jhu.edu  
  
Dave Thomas, MD  Co-Investigator  
  
Courtney Borsuk  Project Director  
 
UNM Division of Epidemiology, Biostatistics and Preventive Medicine  
 
  
  
Statistician  Bert Davis, 
PhD Phone: (505) 272 -4037  
Email:  htdavis@salud.unm.edu  
Biostatistician Cristina 
Murray -Krezan  Phone: 505-272-3205  
Email: cmurray -krezan@salud.unm.edu  
  
New York City Department of Health and Mental Hygiene  
 
Nirah Johnson, LCSW  Co-Investigator  
 
 
 
 
Institutional Review Boards (IRBs)  
Prisma Health -Upstate: Office of Human Research Protection  
Montefiore Medical Center and Albert Einstein College of Medicine:  Montefiore 
Medical Center IRB of the Einstein Human Research Protection Program 
(HRPP)  
 Massachusetts General Hospital :  Partners IRB  
The Johns Hopkins University:  Johns Hopkins Bloomberg School of Public 
Health IRB  
University of Rhode Island: University of Rhode Island IRB and t he Miriam   
Hospital IRB  
West Virginia University :  West Virginia University IRB  
University of California San Francisco:   The Committee on Human Research  
University of New Mexico:  UNM HSC Human Research Protections Office 
University of Washington:  University of Washington IRB  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
5 
 2 Background Information and Scientific Rationale 
2.1 Background Information 
HCV  epidemic  in people  who inject  drugs  (PWID) 
PWID have the highest incidence and prevalence of HCV in the U.S. and globally [1] . In 
the U.S. an estimated 43% of current or former PWID aged 40- 65 years have chronic 
HCV [2]. Prevalence of HCV varies by age and duration of injecting, but meta-analyses 
show that in developed countries , including the U.S., mean cumulative incidence was 
over 20%, and prevalence was 72% in PWID with a history of 10 year of injecting [2] . 
The Centers for Disease Control and Prevention (CDC) estimates at least 30, 000 new 
HCV infections per year  [3], predominantly among PWID, with a 44% increase in the 
number of acute cases from 2010 to 2011 [4] . This increase has been associated with 
an expanding PWID population, especially in non- urban areas across the U.S. [5] , and 
has been related in part to increases in prescription opioids, followed by related 
transitions to injection drug use [6, 7] . Addressing methods to optimize access to 
curative HCV treatment in PWID is a priority given their role in the growing HCV epidemic in the U.S. HCV causes up to 15,000 deaths annually, and is the leading cause of liver transplantation in the U.S. [8 -10]. Treatment effectiveness among PWID is 
crucial because PWID remain the leading risk group for HCV infection [11] . PWID have 
the highest prevalence and incidence of HCV in the U.S., yet HCV treatment is rarely provided to PWID. In two systematic reviews of interferon- based treatment for PWIDs, 
overall SVR was 56%, and response rates were comparable to large RCTs [12, 13] . 
International guidelines from the American Association for the Study of Liver Diseases  
(AASLD )/ Infectious Diseases Society of America ( IDSA ), European Association for the 
Study of the Liver  (EASL ), International Network of Hepatitis in Substance Users  
(INHSU) , and the World Health Organization ( WHO ) all recommend treatment for HCV 
infection among PWID [14-17].  With significant scale up of HCV treatment of PWID, 
overall HCV prevalence could be reduced by up to 75% within 15 years [18] . 
Nevertheless, few data exist on direct -acting antiviral agents (DAAs) treatment 
outcomes in PWID, and therefore PWID are often not eligible to receive DAAs.   
 
HCV  treatment  uptake  among  PWIDs  is limited by  multiple  barriers  
Hepatitis C treatment uptake among PWID has been limited by multiple interrelated barriers at the level of the patient, the provider and the system  (Figure 2)  [19, 20] . 
Patient -level barriers included poor knowledge related to HCV and treatment as well as 
the absence of symptoms, which often results in a low perceived need for treatment. 
These issues are compounded by general barriers to health care access (e.g., having 
insurance, a primary care provider), competing comorbidities, which may require more 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
6 
 
immediate attention as well as factors which impede stability including unemployment, 
unstable housing, lack of transportation, incarceration and ongoing substance use [21-
25]. Providers are often unwilling to prescribe HCV treatment to even former PWID 
because of concerns related to ongoing substance use, low adherence and the potential risk of 
reinfection [20, 25] . 
Some studies have suggested that 
physicians have suboptimal knowledge regarding HCV and its 
treatment which can impact which 
patients get tested, referred and who initiate treatment  [20, 26] . A 
major structural barrier is the cost of 
the medications and the associated 
monitoring. But beyond cost, additional structural barriers include insufficient locations where HCV testing can be performed and where treatment  can be delivered [20, 27] . There is also a 
dearth of providers who can treat HCV and patient navigators dedicated to spearheading HCV -infected PWID and others through treatment. Finally, HCV care has 
historically been delivered in specialist settings which means it is segregated from other services that PWID utilize including primary care, opiate substitution and HIV care.  
 
Efficacy  of new HCV  regimens  for HCV -infected patients  
New direct -acting antiviral agents (DAAs) are efficacious in > 95% of treatment -naïve 
patients [14] . The interferon- free DAA fixed dose combination of ledipasvir 90 mg and 
sofosbuvir 400 mg once daily for 12 weeks is associated with SVR rates of >95% in genotype- 1 infected patients [14] , and is associated with fewer side effects than 
previous regimens: fatigue 13% - 18%, headache 11% - 17%, and nausea 6% - 9%.  
The interferon- free DAA fixed -dose regimen of sofosbuvir 400 mg once- daily (nucleotide 
polymerase) and velpatasvir  100 mg once- daily (NS5A inhibitor) has demonstrated high 
efficacy (95 -96% SVR12) with a treatment duration of 12 weeks in treatment -naïve 
patients with HCV genotypes 1- 6 [28] , and was approved for use by the Food and D rug 
Administration (FDA)  on June 28, 2016. The availability of a simplified IFN -free DAA -
based once- daily regimen of sofosbuvir/ velpatasvir may further enhance the capacity to 
scale- up HCV treatment among PWID. A pan -genotypic regimen can help increase 
access for PWID by eliminating the need for genotypic testing prior to treatment.  Therefore, fixed- dose sofosbuvir/velpatasvir will now be used for this study.  Figure 2: Barriers to Treatment  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
7 
  
PWID  excluded  from  HCV  DAA clinical  trials  
PWID have been excluded from many clinical trials evaluating the efficacy of DAAs . A 
systematic evaluation of exclusion criteria concerning drug and alcohol use in DAA -
based HCV treatment trials for H uman Immunodeficiency Virus (HIV) /HCV co -infected 
persons performed by searching the clinicaltrials.gov website of the U.S. National 
Library of Medicine and N ational Institutes of Health (NIH)  for all available trials through 
May 2013 [29]  identified eighteen clinical trials, involving 9 DAAs (protease, polymerase 
and NS5A inhibitors). Nine trials (50%) excluded individuals with either current or prior 
alcohol, “substance,” or “drug” use. In a majority of these trials (78%), exclusion was 
also based upon site investigators’ perceptions of suitability to participate in the trial. 
Developing consistent, evidence- based criteria concerning substance use will permit 
greater, more equitable access to DAA trials for the  HCV monoinfected and HIV/HCV 
co-infected population s.  Exclusion of important subgroups such as PWID from clinical 
trials has a direct effect on policy and payer’s willingness to provide medications for PWID. The National Association for Medicaid Directors endorsed the University of Oregon report entitled, “Sofosbuvir for the treatment of hepatitis C and evaluation of the 2014 AASLD Treatment Guidelines” which concluded (due to lack of DAA data in PWID) that sofosbuvir -based treatment should be excluded from people who have used 
drugs and alcohol over the last 12 months.  
 
Medicaid restrictions of DAAs  for PWIDs  
The high price of DAAs and high demand has also led payers to institute restrictions on 
their access, although by law Medicaid programs are entitled to a rebate of at least 23% 
[30, 31] . In the U.S., a disproportionate number of people living with HCV are of low - 
income [32, 33] . Most PWID are eligible for HCV therapy reimbursement through 
Medicaid, the jointly funded federal/state partnership that provides health insurance for 
low-income people meeting the program’s eligibility criteria. Each state has wide 
discretion in administering its own Medicaid program.  A systematic evaluation of State 
Medicaid policies for HCV treatment with sofosbuvir in the United States [34]  by 
searching State Medicaid websites between June 23 and December 7, 2014 found that 
overall, 42 states (82%) had publicly available information regarding sofosbuvir 
Medicaid reimbursement criteria. Of these, 88% (n=37) include drug and/or alcohol use in their sofosbuvir eligibility criteria, with 50% requiring a period of abstinence. The majority of states require that patients be abstinent from drug and alcohol for 6 months 
(n=11), while others require abstinence periods of 1 month (n=2), 3 months (n=5) and 
12 months (n=2). The majority of states (n=27, 64%) require urine drug screening prior to treatment to assess drug and/or alcohol use, with only 6 (14%) requiring testing specifically for those with previous drug/alcohol abuse.  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
8 
 Rather than recommending exclusion of PWID, AASLD/IDSA guidelines list PWID as a 
priority group due to potential treatment as prevention benefit [14] . HCV treatment for 
PWID is cost -effective, particularly when the prevention benefits are considered [35] . 
Nevertheless, PWID in the U.S. are systematically denied access to DAAs.   
 
Direct -acting antiviral HCV agents and resistance  
HCV NS5A resistance -associated variants (RAVs) can emerge following unsuccessful 
treatment with an NS5A -inhibitor containing regimen as they have relatively low barriers             
to resistance [36] . RAVS with reduced drug susceptibility are also observed in 
treatment -naïve patients. Patients who did not achieve SVR in Gilead studies evaluating 
direct -acting antiviral regimens including ledipasvir (but not sofosbuvir)  were enrolled in 
a 3-year registry trial. NS5A RAVs were measured at positions 24, 28, 30, 31, 32, 58, 
and 93 because they confer >2.5 reduced susceptibility to ledipasvir in- vitro. At 
baseline, 16% of patients (12/76) of patients treated with ledipasvir had NS5A RAVs. At 
virologic failure, almost all (99%; 72/73) of patients had NS5A RAVs. Moreover, 86% of 
these patients still had NS5A RAVs at follow -up week 96 [37] . NS5A mutations seen in 
monotherapy with velpatasvir include those measured at positions 24, 28, 30, 31, 32, 
58, 92, and 93.  Cross -resistance is observed to all NS5A inhibitors [38] . NS5A inhibitor -
resistant viruses appear to persist for years after treatment failure, and the time needed to clear resistant variants is unknown. Therefore, resistant viruses associated with decreased response to antiviral treatment may be transmitted to other PWID.  
 
HCV  reinfection among PWID  
Reinfection is a potential problem and a barrier to treatment among PWID [23] . Data 
collected to date, principally in PWID who have received interferon- based treatments, 
show reinfection is low: 5.2/100 person years (py) for those who report injection drug 
use after treatment, and less (3.2/100 py) for those who do not report ongoing injection 
drug use [39, 40] . However, recent reports have noted higher rates of reinfection after 
interferon- based treatments in prisoners (8/100 py), HIV/HCV M en who have Sex with 
Men (MSM) (24/100 py), and PWID who relapse to drug use with longer follow -up 
(30/100 py).  [41, 42]   
 Prospective studies assessing HCV reinfection PWID who spontaneously cleared infection [43, 44]  show that to accurately capture reinfection events, genotyping and 
viral sequencing is necessary to distinguish reinfection from intercalation. Without these 
tests, estimates of reinfection incidence were significantly overestimated. Testing 
interval also has an impact on detection of reinfection. In PWID who clear infection spontaneously, testing intervals less frequent than every three months resulted in substantial (by up to 66%) underestimation of reinfection rate [45] . A caveat here is that 
these estimates are from patients who spontaneously clear the virus, and who have 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
9 
 been shown to have a high likelihood of re- clearance of subsequent infections [44, 46, 
47], and immunological responses to reinfection may differ in those with treatment 
induced clearance. Systematic testing (every 3 months after SVR12 in our proposed 
study) to assess the presence of HCV RNA will be essential to accurately determine reinfection events. There is little to  no data on reinfection rates in the era of DAAs.  
2.2  Scientific Rationale  
HCV  treatment  delivered  in primary care settings 
The number of HCV -infected patients who need treatment far exceeds the availability of 
specialists, who are often concentrated in academic medical centers, making access to 
care difficult [48, 49] . When referred to specialty care, 
HCV patients may feel stigmatized by specialist care settings that often exclude PWID from treatment [50 -
52]. Given the simplicity and efficacy of new HCV 
medications, there is an unparalleled opportunity to treat PWID within medical settings that they are already accessing, such as Federally Qualified Health Centers 
(FQHCs). Several studies have also shown that PWID 
are effectively treated for HCV in primary care settings [53-55]. Primary care clinics, such as FQHCs, are 
abundant throughout the U.S. and serve populations at high risk for HCV; studies show 
an HCV prevalence rate of approximately 8% in FQHCs, almost 5x greater than the 
general population [56, 57]. There are 1200 FQHCs nationwide, delivering care to 20,000,000 low -income, underserved patients [58] . These individuals, who frequently 
have minimal education, high unemployment, and live in urban areas, also have high 
rates of substance use and dependence [59, 60] . Of 6.4 million PWIDs nationwide [59] , 
the majority  is not enrolled in substance use disorder  treatment, and instead seeks 
medical care in clinics such as FQHCs [61 -64].  Increased rates of HCV treatment have 
been found in community -based primary care clinics when primary care- based HCV 
treatment is combined with close collaboration between the HCV medical provider and 
an HCV patient navigator. This favorably impacts the HCV Care Cascade as seen in the figures below comparing the cascade in the same community -based clinic with and 
without a primary care based HCV program. [65]  
 
     
Figure 3: FQHCs in the US  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
10 
 Figure 5: HCV Care Cascade  
without Primary Care  
 
 
Evidence -based interventions to enhance assessment, treatment, and adherence 
in the chronic hepatitis C continuum  
With the availability of DAAs  with rate s of SVR reaching 95%, evidence -based 
strategies are urgently needed to achieve real -world effectiveness in challenging patient 
populations such as PWID.  Using I nstitute Of Medicine guidelines, a systematic review 
of evidence- based interventions from PubMED, Medline, Google Scholar, EmBASE, 
and PsychInfo bibliographic data bases and citation indices [16] identified evidence-
based interventions to enhance HCV assessment, treatment, and adherence in 4 
categories: 1) diagnosis; 2) linkage to care; 3) pre- therapeutic evaluation or treatment 
initiation; or 4) treatment adherence. Several interventions introduced on- site HCV care 
with patients in previously established opiate agonist treatment programs and showed 
comparable rates of uptake and SVR to non- PWID populations [66-71].  
 
Common to all of these interventions is a multidisciplinary approach that combines medical and addiction treatment with intensive social support [13]. Similarly, primary 
care settings represent key opportunities for HCV care linkage interventions, often within clinics that have engaged PWID. These studies demonstrated that patients with ongoing drug use and psychiatric comorbidity can be effectively linked to care and treated within these settings [54, 55, 69, 72- 74]. Peer -driven interventions including 
weekly support groups have demonstrated high uptake of HCV treatment and SVR 
rates among PWIDs [75 -77]. Additional studies are needed to measure the impact of 
peer-driven interventions [78, 79]  in the eras of DAAs.  
 
When PWID are surveyed to assess HCV treatment knowledge and barriers to 
treatment initiation [22] , interest [80, 81] , and willingness to receive treatment [82] , 
treatment -naïve patients were more willing to enter HCV treatment program if they 
perceived themselves at risk for cirrhosis or liver cancer [81] or had more knowledge 
about HCV [82] . A randomized control trial (RCT)  of patient navigation intervention 
consisting of motivational interviewing, education, and case management was 154
122
67
44
176 4
050100150200
Figure 4: HCV Care Cascade  
with Onsite Primary Care  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
11 
 associated with increased HCV clinic visit attendance among patients in methadone 
maintenance [83]. With the simplicity of treatment with newer DAAs (one pill daily), 
treatment has moved towards primary care venues [84] .  
 The 2015 INSHU HCV Clinical Guidelines for PWID [15]  recommends that: (I) Models of 
HCV care integrated within addiction treatment and primary care health centers, as well 
as prisons, allow successful pre- therapeutic assessment (Class I, Level B); II) Peer -
driven interventions delivered within opiate substitution treatment settings may lead to 
higher rates of treatment initiation (Class IIa, Level C); and (III) Care coordination in conjunction with behavioral interventions can increase likelihood of PWID being 
evaluated and initiating treatment (Class I, Level B). Though on- site multidisciplinary 
models of care have demonstrated good outcomes for PWID, optimal models of care 
must be studied [85].  
 
Directly Observed Therapy  
Similar to the implementation of directly administered antiretroviral therapy, or directly 
observed therapy (DOT) for HIV [86, 87] , several interventions involved the provision of 
HCV treatment as DOT [88] . By using a modified DOT approach (mDOT) to observe 
only the morning dose of ribavirin or weekly injections of interferon, HCV treatment was 
successfully delivered in opiate agonist treatment programs [68, 69, 89], prison settings [90], and community health centers [75] . Another study provided ribavirin as once- daily 
DOT, demonstrating extremely high rates of SVR among patients stably maintained on opioid substitution therapy [91] .  
 
RCT of directly observed HAART in methadone- maintained patients  
In an RCT of DOT with Highly Active A nti-Retroviral Therapy (HAART)  in HIV -infected 
drug users in methadone clinics seventy -seven participants were randomized to a 24-
week DOT intervention or treatment as usual (TAU), with 86% study retention at 24 weeks. Participants randomized to DOT (v. TAU) had greater adherence (mean 
adherence: 86% v. 56%, p<0.0001) and VL decreased by 0.52 log10 copies/ml in the 
DOT group while it remained stable in the TAU group (p<0.01).  More DOT than TAU participants had undetectable viral load (71% vs. 44%, p=0.03) [86] . Active drug use 
decreased adherence, but the negative impact of drug use on adherence was 
eliminated by DOT [92]. By 3 months after DOT ended, differences in both adherence 
and viral load between DOT and TAU had extinguished [93] . These data demonstrate 
that DOT is associated with improved HIV virological outcomes among methadone-
maintained patients, including active drug users, and that it should be continued long-
term for durable effect. In several other HIV studies, treatment adherence and 
virological outcomes are improved among PWID when DOT is administered at methadone clinics and in community settings [94, 95] . 
 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
12 
  
Study  of HCV treatment  in methadone -maintained patients  
In 2003, a study within a methadone maintenance treatment program included directly -
administered weekly interferon in addition to screening, assessment of treatment 
eligibility, psychiatric services, and on -site antiviral therapy [96].  Of 73 patients, most 
were Latino (67%) or African- American (12%), nearly half (49%) had used illicit 
substances in the 6 months before initiating treatment, 32% were HIV -infected, and 
current psychiatric illness was common (67%). Most (86%) completed 12 weeks of HCV treatment and 45% achieved SVR, including 40% of genotype- 1 patients. Though 30% 
used illicit drugs during HCV treatment, there was no association between illicit drug 
use and virological outcomes. These results demonstrate that PWID with complex 
medical and psychiatric comorbidities can be effectively treated for HCV with co- located 
on-site care.  
However, it is unknown which interventions (on- site care v.  DOT injections) contributed 
to the observed outcomes [70, 96, 97]. In 2008 a pilot RCT of modified DOT (mDOT), extended the DOT strategy to the oral medication ribavirin. This trial (n=80) was designed to test the efficacy of 2 versions of mDOT [89] . The primary objective was to 
determine whether enhanced DOT with both interferon (IFN)  plus ribavirin is more 
efficacious than standard DOT with weekly provider -administered IFN and self -
administered ribavirin for improving adherence.  Significant differences in pill count adherence between the treatment arms were observed (88% in mDOT arm vs. 77% in the treatment as usual, or TAU arm, p=0.02) [98] . In addition, 81% of mDOT subjects 
achieved ≥ 80% adherence v. 53% in the TAU arm (p=0.09). Only 16% discontinued 
treatment, and among genotype- 1 infected patients, 55% achieved SVR (half active 
drug users) [94] .  
In 2009, treatment for genotype- 1 patients in the study was changed to include DAAs 
(telaprevir or boceprevir) in combination with pegylated interferon and ribavirin. Of the first
 50 patients treated with DAAs (either telaprevir or boceprevir in combination with 
pegylated interferon and ribavirin), 62% achieved SVR despite high rates of recent drug 
use prior to treatment (52%), ongoing drug use during treatment (45%) and psychiatric comorbidity (86%) [98]. 
Since Jan uary 2014, sofosbuvir -based regimens have been implemented in 115 
methadone- maintained PWID including 51 genotype- 1 patients with highly efficacious, 
all-oral regimens of sofosbuvir in combination with simeprevir (n=29) OR fixed- dose 
sofosbuvir in combination with ledipasvir (n=24). To date, almost all patients (98%) are 
either undetectable or have HCV VL<15 I nternational Units (IU) /ml.  Among 31 who 
have completed treatment, 13 have achieved an SVR12, 15 have an end of treatment 
response (ETR) and are awaiting SVR12 determination, 2 are awaiting ETR 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
13 
 determination, and 1 had a relapse after ETR. Twenty patients remain on treatment, 
and all are either undetectable (n=13), have HCV V iral Load (VL) <15 IU/ml (n=3) at 
week 4, or have not yet reached week 4 (n=4).  No patients have discontinued treatment.  
 
Models  of Patient  Navigation  
First used with cancer patients, the principal goal of patient navigation is to assist 
patients to move through the medical care system. There are four principal roles of PNs: 
1) coordinating treatment; 2) health education and promotion; 3) assisting patients to 
overcome personal barriers; and 4) providing psychosocial support. In a multi -site U.S. 
study, PNs assisting HIV -positive individuals resulted in higher adherence to medical 
care appointments and a significant increase in those achieving an undetectable viral load [99] . HCV models of care integrating PNs within substance use  disorder  treatment 
and community health centers have been widely implemented in several states, including New York [100, 101]. PN models integrating peer support through on- site 
support groups have led to high rates of treatment uptake and SVR in methadone maintenance treatment patients including those using drugs, and peers have led to 
improved outcomes in several other chronic diseases [102, 103] . PN models with 
integrated peer support may improve patient -centered outcomes such as self -efficacy, 
shame and stigma. However, the best model of care for treating HCV in PWID is 
unknown, as is which model is most acceptable to patients. Despite availability of highly 
efficacious regimens, PWID face more barriers to treatment than ever, due to continued 
concerns from providers regarding poor adherence and reinfection, and restrictions from payers due to lack of data with new DAAs  [104] . 
2.3 Potential Risks and Benefits   
Potential Risks  
The risks of the study include:  
1) Inconvenience of attending research visits, 2) discomfort associated with research interviews, 3) venipuncture, 4) discomfort associated with directly observed 
medication administration or with a patient navigator , and 5) confidentiality issues 
associated with research encounters. These risks will be discussed with potential 
participants during the informed consent process. The alternative of not participating in the study will be discussed with participants during the informed consent process.  
 
Inconvenience of attending research visits : This study requires that participants 
participate in face- to-face encounters with the research staff  at visits 0, 1, 2, 3, 4, 5, 
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and 17  over a period of 42 -45 months . 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
14 
 Inconvenience of study participants attending research visits will be addressed by 1) 
reimbursement for time spent in research encounters ($20 for each research visit 
and $5 for each returned weekly blister pack),  2) conducting assessments on- site in 
participants’ OTPs, when allowed by the OTP , or 3) conducting assessments at  
community research sites which may be more conveniently located for participants 
that reside nearby.  Additionally, participants will be informed by the research staff 
during the informed consent process that they can choose to withdraw from the study at any point. We will also provide rest and refreshment breaks  during visits . 
Discomfort associated with research interviews : Surveys will as sess health status, 
substance use, psychiatric symptoms, stigma, shame, medication adherence and 
other sensitive subjects. It is possible that survey questions could be uncomfortable for participants. Participants will be told that they may choose to stop the interview or withdraw from the study if they find the questions troubling.  
Discomfort associated with directly observed therapy  or
  patient navigator : 
Participants may feel uncomfortable with receiving m DOT  or with a patient navigator .  
There may be discomfort with the additional level of scrutiny or interaction associated with these models of care.  
 
Confidentiality issues in research encounters : The risk of study participation includes 
possible loss of confidentiality.  Risks to privacy and confidentiality exist with all human research.  Because this project focuses on people who inject drugs, confidentiality is a major concern. The study will be collecting personal information from participants to facilitate follow up, and will be asking questions about sensitive data including illicit drug 
use and alcohol use, mental health, and health status. Subjects will be assigned a 
unique study identification number which will be used on case report forms (CRFs), and 
specimens collected for laboratory analyses.  No samples or data will be labeled with the subject’s name.  The key to subjects’ names will be accessible only to the study co-
principal investigators, and hard- copies and electronic copies of data will be stored in 
secured locations.  
Venipuncture:  The risk from venipuncture is minimal but may include anxiety, pain, 
bruising, and infection.  
Potential Benefits  
Participants assigned to the m DOT or PN arms of this study may benefit by 
achieving high levels of treatment initiation, adherence and improved HCV 
outcomes. Participants will receive access to medications that are often denied by 
payers and providers to PWID. The patient -centered models of HCV care ( mDOT 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
15 
 and PN) may also provide a mechanism for rapid identification of potential adverse 
medication effects, and this may result in fewer adverse events, decreased morbidity 
from HCV, and improved psychosocial functioning. Given the low risk presented by 
participation in this study and the high potential for direct benefit of cure if the participant completes HCV treatment, the risk/benefit ratio is very favorable . 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
16 
 3 Study Objectives  
 
3.1 Primary Objective  
 
To determine whether  SVR-12 rates are higher among those randomized to mDOT 
compared to those randomized to PN , among PWID treated for HCV  at OTPs and 
communit y health centers . 
 
3.2 Secondary Objective 1  
 To examine the following outcomes overall and by randomization arm ( mDOT 
compared to PN)  among PWID treated at OTP s and co mmunity  health centers :  
(i) Treatment initiation:  whether a higher proportion of participants in the PN arm i nitiate treatment compared to mDOT arm ;   
(ii) Adherence (≥80% of prescribed medication taken) :  whether a higher 
proportion of those in the mDOT arm are adherent compared to PN arm;  
(iii) Treatment completion (finishing  100% of  prescribed 12- week course) :  
whether a higher proportion of participants in the mDOT arm complete 
treatment compared to PN arm;   
(iv) Drug resistance: whether the proportion who develop drug resistance is higher in the PN arm compared to mDO T arm;  
(v) Reinfection : whether (a) rate (incidence), and the (b) proportion who 
become reinfected with HCV is higher in the PN arm compared to mDO T 
arm; 
 
Comparisons  will be performed to determine the proportion of subjects in each arm 
who: a) initiate treatment; b) adhere to antiviral treatment; c) complete antiviral 
treatment; d) attain SVR (cure); e) develop drug resistance; f) reinfection.  We will also 
conduct time to event analyses to examine drug resistance and reinfection outcomes.  
Subgroup analyses will be performed to assess  differences in outcomes among those 
randomized to PN vs. mDOT in specific sub -populations.  
 
3.3 Secondary Objective 2 
 To examine factors associated with key study outcomes (treatment init iation, 
adherence, SVR, drug resistance and HCV reinfection) using quantitative and qualitative methods.  
 
Quantitative methods :  We  will examine associations between psychosocial factors 
such as homelessness, co- morbid mental illness, poor social support, and high 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
17 
 levels of shame and stigma, with key study outcomes described above. It is 
hypothesize d that these psychosocial variables are associated with lower rates of 
adherence and SVR in the PN arm, but not the m DOT arm; and associated with 
lower rates of treatment initiation in the mDOT arm, but not the PN arm.  
 
Qualitative methods: Qualitative methods  will be used to conduct an interview study 
focusing on pragmatic concerns and experiences of key stakeholders. Two key groups of stakeholders , patients and patient navigators, will be interviewed 
regarding the barriers and facilitators to successful treatment uptake. In the patient group, up to 15 patients from each site will be recruited. Recruitment will be of both 
successful and unsuccessful participants along the pathway to care and use structured comparisons to understand differences between those who have benefited from the intervention and those who have not. In years 1- 2 of the project 
period, preliminary results of these analyses will be used for formative evaluation 
purposes, feeding back results to study leaders in order to help improve/adapt 
study features and make the interventions more patient centered. In years 3-6 of 
the project, the data will contribute to the mixed methods summative evaluation to understand barriers and facilitators to program success.  Protocol and 
implementation  details for qualitative methods are detailed in the Implementation 
Study Protocol ( Appendix 3).  
 
 
 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
18 
 4 Study Design  
 
Overview of study approach  
This is a multi- site national study (8 U.S. cities), where up to 1000 HCV -infected 
PWIDs (injecting illicit substances within 3 months of screening)  will be randomized 
to either PN plus weekly or biweekly blister pack dispensation versus m DOT . Among 
patients who go on to initiate HCV treatment (n=600 targeted) with a once- daily 
combination regimen of fixed -dose sofosbuvir/velpatasvir, a comparison will be 
conducted of the proportion of patients in each arm who: (a) optimally adhere 
(>80%), (b) complete treatment, (c) achieve SVR, and (d) develop resistance. The 
primary outcome will be SVR. The  8 sites  offer geographic and policy diversity:  New 
York City, Baltimore, Providence, Boston,  Morgantown, Seattle, San Francisco, and 
Albuquerque.  
 Participants will be recruited from diverse venues: OTP s, community health centers, 
syringe exchange programs, community -based organizations, homeless programs, 
and cohorts established by research studies.  The clinical sites will determine eligibility based on clinical records, or on- site testing including HCV tests (anti-HCV 
and HCV viremia) . Study participants will be screened, consented and enrolled on-
site at OTP  and non- OTP settings. There will be differences in linkage, engagement 
and outreach at each site. These procedures will be documented in site specific operating manuals.   
Patients will be randomized to one of two models of care: patient navigation (PN) vs. 
modified directly observed treatment ( mDOT).   Patients enrolled from OTP s who 
are receiving methadone and randomized to mDOT  will receive doses of once daily 
medication at the same time as they receive methadone. Patients enrolled from community health settings and randomized to m DOT may receive observed doses  
through use of miDOT (emocha Mobile Health, Inc.) , a mobile health app on a 
smartphone, or at the  CHC.  Subjects randomized to PN will receive a standardized 
PN intervention.  Sites also have the option to offer all subjects  optional  additional 
support through a peer -led support group.  
 Participant s will be followed for up to 180 weeks: 12 weeks of pre- treatment 
evaluation, 12 weeks of treatment, 12 weeks of follow -up to determine SVR12, and 
144 weeks of follow -up to determine long- term SVR and reinfection. Data sources 
will include clinical lab and imaging results from medical records, blood tests (HCV viral load during long- term follow -up and resistance assays), urine toxicology, 
questionnaires, electronic monitors for assessing adherence, and interview s. 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
19 
 5 Study Population 
Participants will be recruited from a diverse national patient population from at least 16 
health centers in 8 states - all with on -site HCV care (8 OTPs and 8 community health 
centers – Table 1). Target enrollment is up to 1000 PWID (to target 600 PWID initiating 
treatment) with the following characteristics ( Table 2): Caucasian (55%), Latino (21%), 
and African American (20%), male (61%), and mean age of 44 years; 28% will be 
HIV/HCV co -infected. Within the 8 OTPs, there is a potential pool of 4790 mono-
infected and 510 co- infected patients. Within the 8 community health  centers, there is a 
potential participant pool of 2809 mono- infected and 1433 co-in fected patients. 
Community enrollment has a pool of >4000 HCV -infected clients in the community. 
With over 13,000 HCV -infected patients, target enrollment is 1000 PWID.  Eligibility for 
HCV treatment will be determined by subjects’ on- site medical care providers, as part 
of routine clinical care.  
Table 1: HCV -infected Patients at OTP s and Community Health Centers  
City,  State  OTP #HCV  #HIV/HCV  Community  Health  Center  #HCV  #HIV/HCV  
Bronx,  NY Melrose  Wellness  
Center  1500  250 Comprehensive  Health  Care  
Center  400 60 
Providence,  RI CODAC  Behavioral  
Health  Services 750 25 Miriam Hospital  
Brown  Infectious  Diseases  
Center  50 400 
Albuquerque,  NM UNM  ASAP  720 25 Truman  Health  Services  20 200 
San Francisco,  CA Ward 93 Opiate 
Treatment Outpatient 
Program  325 70 PHP Ward  86 and Tom Waddell 
Urban Health Clinic  100 213 
Boston,  MA Bay Cove  Human  
Services  150 10 MGH  and CCHI  300 100 
Baltimore,  MD Reach  Health  Services  300 60 Comprehensive  Care  Practice  1000  100 
Seattle,  WA Evergreen  Treatment  
Services  700 50 Harborview  Adult  Medicine  884 250 
Morgantown, WV  Valley Alliance  
Treatment Services  345 20 Milan Puskar Health Right   110 20 
Total   4790  510  2809  1433  
 
 
  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
20 
  
Table 2: Demographic, Clinical, and Psychosocial Characteristics of HCV -infected Patients  
State  NY MA RI WV WA NM CA MD Total  
Age (mean)  49.0  40.5  55.0  30.0  40.0  41.5  48.0  46.5  43.9  
Gender  
 Male   
 62%  (78)  
 68%  (85)  
 41%  (51)  
 55%  (69)  
 63%  (78)  
 70%  (88)  
 82%  (102)   
 50%  (63)  
 61%  (614)  
Ethnicity   
 Latino   
 65%  (81)  
 13%  (16)  
 15%  (19)  
 0% (0)  
 5% (6)  
 52%  (65)  
 17%  (21)  
 1% (1)  
 21%  (213)  
Race/ethnicity  
 Caucasian   
 African -Am 
 Native -Am  
 Asian  
 Other   
 20%  (25) 
 25%  (31) 
 0% (0) 
 0% (0) 
 55%  (69)  
 73%  (91) 
 20%  (25) 
 1% (1) 
 1% (1) 
 5% (6)  
 37%  (46) 
 31%  (39) 
 11%  (14) 
 0% (0) 
 21%  (26)  
 98%  (118)  
 2% (1) 
 0% (0) 
 0% (0) 
 2% (3)  
 62%  (78) 
 24%  (30) 
 2% (3) 
 2% (3) 
 10%  (13)  
 76%  (95) 
 3% (4) 
 9% (11) 
 1% (1) 
 11%  (14)  
 50%  (63) 
 25%  (31) 
 1% (3) 
 4% (5) 
 20%  (25)  
 25%  (31) 
 75%  (65) 
 0% (0) 
 0% (0) 
 0% (0)  
 55%  (546)  
 20%  (196)  
 3% (32) 
 1% (13) 
 21%  (211)  
Cirrhosis   34%  (43)  15%  (19)  45%  (56)  7.5%  (9)  15%  (19)  33%  (41)  14%  (18)  5% (6)  21%  (211)  
HIV-infected   20%  (25)  13%  (16)  50%  (62)  2.0%  (3 )  5% (6)  47%  (59)  70%  (88)  13%  (16)  28%  (336)  
Unstably  housed   20%  (25)  35%  (44)  11%  (14)  13%  (16)  28%  (35)  25%  (31)  60%  (75)  15%  (19)  26%  (261)  
Psych   75%  (94)  67%  (84)  63%  (78)  45%  (54)  60%  (75)  35%  (44)  71%  (89)  25%  (31)  55%  (549)  
 
The participants in the proposed trial will be 1000 patients recruited from 8 cities: Bronx (Montefiore Medical Center), Baltimore (John Hopkins University), Providence (The University of Rhode Island),  Boston (Harvard School of Medicine), Morgantown 
(West Virginia University), San Francisco (UCSF), Albuquerque (University of New 
Mexico), and Seattle (University of Washington).  
5.1 Inclusion Criteria  
Inclusion criteria that must be met before enrollment:  
 
• Current  HCV  infection  (HCV viremic ) 
• HCV Viral load test from any time  
• Must have had the followi ng tests performed in the past 12 months:  AST, ALT, 
platelets  
• Actively injecting drugs (any substance within 3 months  of screening)  
• Not previously treated with HCV direct -acting antiviral medications  
• Age 18 –  70 
• Willing to receive HCV treatment with sofosbuvir/velpatasvir  
• Willing to be randomized to either PN vs mDOT  
• If receiving methadone , be attending or be willing to attend OTP a minimum of 
5 times per week  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
21 
 • Able to provide informed consent  
• English or Spanish fluency  
5.2 Exclusion Criteria  
Exclusion criteria will include:  
• Pregnant or breast feeding  
• Hepatocellular carcinoma  
 
5.3 Re-Screening  
Subjects can be rescreened if  they fail screening. Participants can be rescreened only 
one time following first screen failure.  
5.4 Randomization 
Up to 1000 patients will be recruited, with patients randomized to PN or m DOT in a 
1:1 ratio (500 subjects in each group) in variable block sizes of 2- 6 via central, 
computer -generated randomization provided by the UNM Statistical and Data 
Coordinating Center (SDCC) . Randomization will occur in blocks to ensure 
comparison groups of approximately equal size. Given that the intervention will not be 
blinded, block size will vary to prevent anticipation of treatment arm assignment.   
 
Two special randomization strategies (stratification and blocking) will be used to avert 
imbalances in prognostic factors or treatment settings, and to ensure comparison groups of approximately equal size. Participants will be stratified by 3 factors: city, OTP vs. community health center and stage of liver disease (cirrhosis v. no cirrhosis).  
 In addition, adaptive re -weighting of random allocation in a pseudo urn randomization 
fashion will be made when N ~300 has been enrolled to balance the sample size 
between mDOT and PN arms. Specifically, as we hypothesize that number of 
randomized subjects who will initiate treatment will be larger in the PN arm, unbalancing 
between arms is likely to occur during the course of the study. Of note, therefore, a randomized subject will not necessary be a clinical treatment subject but will be 
included in the comparison of treatment initiation.    
 To adjust for this potential unbalance, we will adjust random ization based on observed 
allocation ratio at the middle of trial if the overall allocation difference is greater than 5% 
(i.e., <47.5% vs. 52.5%).  
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
22 
 Storage and dispens ing of random allocation codes will be made in a centralized 
fashion. The UNM SDCC will generate and store the codes for all sites and types of 
clinics, and will be embedded into the R esearch and E lectronic Data Capture 
(REDCap)  data management system in the backend so that the identification of a 
treatment assignment will be ready and immediate without contacting the coordinating 
center when requested through the REDCap electronic request form by a responsible 
research staff at  the sites whenever a new eligible participant  is enrolled.  The UNM 
SDCC will also be responsible for  conducting re-weighted randomization, if 
necessary, at the middle of the trial .  
 Randomization will occur at enrollment, however research staff will wait until after the 
baseline assessments have been conducted to reveal the randomization to the participant, to avoid bias during baseline data collection.  
5.5 Withdrawal  
Reasons for Withdrawal  
Subjects may withdraw or be withdrawn for any of the reasons given below.  The reason for withdrawal will be recorded on a  CRF.  
 In accordance with the current revision of the Declaration of Helsinki (amended October 
2000, with additional footnotes added 2002 and 2004) and any other applicable 
regulations, a subject has the right to withdraw from the study at any time and for any reason and is not obliged to give his or her reasons for doing so.  The Investigator may withdraw the subject at any time in the best interests of the subject’s health and well -
being.  In addition , the subject may withdraw/be withdrawn for any of the following 
reasons:  
• Administrative decision by the Investigator.  
• Ineligibility (either arising during the study or retrospective, having been overlooked at screening).  
• Significant protocol deviation.  
• Subject non- compliance with study requirements.  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
23 
 6 Investigational Interventions  
 
This is multi- site national study (8 U.S. cities), where up to 1000 HCV -infected PWIDs 
(injecting illicit substances within the last 3 months) will be randomized to either PN plus blister pack dispensation (weekly or every other week)  versus mDOT.  
6.1 modified Directly Observed Treatment  
6.1.1 OTP Setting  
Observation of HCV medication administration will be linked to  methadone visits  
among patients receiving methadone. The schedule of five days per week w ill be 
considered modified DOT  (mDOT). Participants enrolled in the mDOT arm through 
the OTP who are not taking methadone, but another version of opioid agonist 
treatment (OAT) , such as buprenorphine, will follow the mDOT protocol for  
community health center  participants.  
Method of observation:  Subjects in the mDOT arm will receive: 1) 5  directly 
observed doses per week  (from a blister pack ) at the same time as they receive 
methadone, and 2) take- home  doses packaged in blister packs for self -
administration on other days . In addition, the observing staff will: (i) notify clinicians 
when doses are declined or missed and (ii) refer subjects to clinicians as necessary.    
Administration  of Medication:  Medications will be packed in labeled blister packs .  
For participants who are receiving methadone and attending clinic 5 days/week, 
medication  will be kept at the clinic where research/clinical staff will observe them 
taking the medications.  Participants will also receive take- home doses packaged in 
blister pack s for the days that they are not observed at the methadone clinic .  Blister 
packs will be returned to research staff at the next research visit .   
Each time a subject misses an observed dose, there should be an assessment by 
the observer: the observer will ask whether the patient missed that day's dose, took 
a rescue dose, or took medication from another source.  
 Rescue Doses: E ach participant will receive a container  labeled with the contents, 
containing up to two  dose s of HCV treatment medication.  In the event the participant 
misses the opportunity to take an observed dose at the OTP , they can take one of the 
rescue doses instead.  This container will be either a pill case or a container specified 
by the local site. When the participant presents to the program  for the next observed 
dose, the prior missed dose will be given to the participant to replace the rescue dose 
that was taken for any future events.  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
24 
 Record keeping:  Each time a subject misses an observed dose, there should be an 
assessment by the observer: the observer will ask whether the patient missed that 
day's dose, took a rescue dose, or took medication from another source.  
Staff that observe the participant taking their medication will log the information on a 
standardized log.  Adherence will be measured with standardized forms each week by Study Coordinators and will include pi ll counts of blister packs.  
 Participants that choose to leave the OTP during treatment will have the potential to remain in the study by being transferred to the Community Health Center.  
 6.1.2 Community  Health C enter  Setting  
This intervention is considered modified DOT (mDOT) since between 3-7 weekly 
doses will be directly observed.  
 Method of Observation:  All observed doses will be observed using electronic DOT 
(eDOT), via the mobile health smartphone app miDOT (developed by emocha Mobile Health, Inc. ).  Participants will be provided with a smartphone that is pre- loaded with a 
data/minutes plan and the miDOT app.  Research staff will train the participant on 
how to use the app.   Using the app, participants will take a video of themselves taking 
their HCV medication, then upload the video to the database maintained by emocha.  
Research staff will review these videos.  On the day of medication pick -up, research 
staff will be available to provide technical assistance with that day’s video.  
 If a participant loses the study -provided phone or is  otherwise unable/unwilling to use 
the miDOT app, participants will receive mDOT three times per week at the CHC by 
clinic/research staff. The remaining doses will be taken by the participant outside of 
the clinic . 
 Dispensing of Medication:  Participants participating in mDOT will receive their 
medications in weekly blister packs once a week.  Participants will return blister 
pack s (with or without any remaining medication) at their next research visit .  If the 
participant is not using the emocha miDOT app, their medication will be packaged in 
weekly blister packs and the participant will receive three observed doses at the clinic by clinical or research staff.  The blister pack will remain with staff during the 
week until the participant has received their last observed dose for the week.  The 
participant will then receive the blister pack with remaining doses to take home as unobserved doses.  For any unobserved doses during the week prior to their final observed dose of the week, the participant will pop out the pill from the blister pack 
and take it home in a labeled pill case.   
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
25 
 Research or clinic staff will: (i) notify clinicians when doses were declined or not 
observed and (ii) refer subjects to clinicians as necessary.  
 
Rescue Doses:  Each participant will receive a container,  labeled with the contents, 
containing up to two  dose s of HCV treatment medication. I n the event the participant 
misses the opportunity to take an observed dose at the OTP, he/she can take one of 
the rescue doses instead. This container will be either a pill case or a container 
specified by the local site. When the participant presents to the program for the next 
observed dose, the prior missed dose will be given to the participant to replace the 
rescue dose that was taken for any future events.  
 Record keeping:  Research staff will review the m iDOT videos, and record the date 
and time that the dose was taken.  For participants not utilizing miDOT, clinic or 
research staff will observe the participant taking their medication and log the 
information on a standardized log.  Adherence will be measured with standardized 
forms each week by Study Coordinators and will include pi ll counts . 
 
Adherence will be measured and logged with standardized forms each week by 
research staff  and will include pill counts of blister packs.  
6.2 Patient Navi gation  
The study will follow a PN model developed by New York City Department of Health 
(DOH) in collaboration with Montefiore Medical Center and the community .  HCV PNs 
have the following functions: 1) coordination of treatment; 2) health education and 
promotion; 3) assisting patients to overcome barriers; and 4) psychosocial support. Additional support may be offered through optional  weekly peer -led support group 
(see below  Section 6.3 ).  Details of the PN protocol and materials are in the Patient 
Navigator Manual . Implementation of the PN protocol will differ by site based on the 
structure of the PN groups. Sites will document site -specific  procedures in their 
operating manuals.  
 
Packing of Pills for Patient Navigation Arm  
For the PN arm pills will be packed in two -week blister packs and dispensed every other 
week .  If participant is having difficulty with adherence on the biweekly schedule, the 
provider wi ll assess changing the dispensing to weekly, and document the reasons for 
changing.  No doses will be observed so even if patient is coming to the clinic  weekly 
and picking up medications, all doses will be self -administered.  
 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
26 
 6.3 Education and Peer Support  
 
Optional Peer Support - Weekly Support Groups:  
Peer support groups may be available at all sites for all participants, depending on 
local factors.  Peer support groups will provide support and education covering the 
following topics: natural history, goals of treatment, treatment regimen and side 
effects, adherence (including strategies), drug and alcohol abuse, and transmission / reinfection. Support groups will receive HCV support group materials developed by Project Inform, Montefiore Medical Center, and HCV Mentor and Support Group; 
each group will be guided by local advisory boards based on local patient 
preferences and barriers. Availability , structure and frequency of peer support and 
education will differ by site. Sites will document available peer support and education resources , structure  and attendance in a site log. 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
27 
 7 Study Procedures/Evaluations  
 
7.1 Clinical Evaluations  
 
Individual medical records will be reviewed to evaluate HCV -related labs and dates 
performed (HCV viral load, genotype and subtype , FIB-4 (AST, ALT, and Platelets), 
total bilirubin, albumin, prothrombin time, FibroSURE  (if available) , Fibroscan/liver 
biopsy (if available ), abdominal imaging results (ultrasound/MRI) if available,  and other 
medical history including the most recent HIV test.  
 To determine presence of cirrhosis, all subjects will have a FIB-4 biom arker test 
calculated at enrollment  (obtained by chart review) . If FIB -4>3.25, the patient is 
considered to have advanced cirrhosis .  If available, results of fibroscan, liver biopsy or 
imaging study (ultrasound/ CT/MRI c/w cirrhosis) will be used for stratific ation instead of 
FIB-4. 
 Psychiatric status will be assessed in all participants using structured instruments, including: 1) PHQ -9 to assess for depression and 2) the GAD -7 to assess for anxiety.  
Suicid al ideation will trigger a  psychiatric referral.  
7.2 Laboratory Evaluations  
HCV Viremia : Blood for HCV viral loads will be sent directly to Quest Diagnostics. 
Twenty  mL of blood will be collected at visits 5, 6, 7, 8, 9, 10, 11, 12 ,13, 14, 15, 16 and 
17 for HCV viremia testing and archiving.  Specimens will be identified only by study ID 
number or bar -code, and will also be labeled with the name of the research study, the 
date and time of collection, and the specimen number. Each site will send blood samples directly to Quest .  Results which will be entered into the study data system.  
Resistance testing:  For subjects who fail to achieve SVR or show evidence of 
reinfection, NS5A/NS5B resistance testing will be performed on the baseline , and either 
treatment failure visit (unscheduled)  or Visit 5 specimens. The second time point will be 
determined by when treatment failure is first identified. The specimen for “treatment 
failure visit” will be used if the subject fails treatment during the 12 weeks of treatment, 
and the specimen for “Visit 5” will be used if the subject fails treatment after the 
treatment period.   All specimens for resistance testing will be shipped to Montefiore 
CRC, and banked. Batched runs for resistance testing will be run at Monogram.  
Biorepository specimen:  Blood specimens will be c ollected at research visits 1, 5, 6, 7, 
8, 9, 10, 11, 12, 13, 14, 15, 16 and 17.  At Visit 1, twenty  mL of blood will be drawn and 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
28 
 stored locally until sent to the study biorepository.  A biorepository will be established at 
Prima Health -Upstate  for archiving stored blood for future studies . At all other visits, 
twenty mL of blood will be drawn and sent to Quest for HCV VL testing and temporary 
archiving before being sent to Prisma Health -Upstate ’s Biorepository . 
 
Toxicology :  Urine toxicology tests (American Bio Medica  Corporation RapidTox  Point of 
Care (P OC) test) will be performed at research visits 1, 2, 3, 4, 5, 7, 9, 11, 13 , 15, and 
17.  At these research visits, the RA will ask subjects to provide a urine specimen, 
unobserved,  in a private bathroom. Collection containers and biohazard bags will be 
available to the study staff from the commercial laboratory. Specimens will be labeled with the name of the research study, the date and time of collection, and the specimen number; no names or other identifying information will be used.  The specimen number will be generated using the subject’s study ID number, the letters UT (to denote urine 
toxicology test), and the visit number. The RA will perform the point of care test (results 
back in 5 minutes).  Urine will be tested for multiple substances: amphetamines, barbiturate, benzodiazepine, buprenorphine, cocaine,  marijuana,  methadone, 
methamphetamine, opiates, and oxycodone. Results will be recorded in R EDCap.   
Urine toxicology results are confidential and will only be used for study purposes, not recorded in the participant’s clinical record.  
7.3 Non-Clinical Evaluations  
Participant surveys :  At baseline and every research visit, participants will answer 
surveys administered by the research assistants who will either record the responses 
directly into the REDCap database or onto a paper form, then entered into the REDCap database after the research visit is finished.  
 
Medical record :  HCV viral load will be obtained when possible by chart review. 
Information on treatment interruptions and discontinuation will be obtained from medical records.  
Adherence by electronic monitors (Med- i
 c®) and self -report :   
Adherence to medications dispensed in electronic blister packs will be measured by 
electronic compliance monitoring for blistered medications with an attached Med- ic® 
device . Med -ic® is an innovative stick -on paper label for medication blisters that 
provides a disposable method to measure adherence ( 117). Med -ic® packages yield 
99.6% event accuracy (time of dose removal correctly recorded within + 2 minutes). 
This technology will allow tracking of medication usage from weekly blister packs 
prepared by the local pharmacist s. Blister packs will be pre -fitted with labels and 
electronic tags.  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
29 
 In the PN arm, subjects will receive their HCV medication from the medical staff, 
packaged in 7 -14 day  blister packs, either weekly or every other week (standard) , 
depending upon the determination of the provider after discussion  with the participant . 
Used blister packs will be returned at research visits for downloading adherence data.  
In the mDOT arm, subjects (enrolled in the OTP) will take observed doses at the OTP. 
The date and time of the dose will be recorded in the mDOT log . Seven- day blister 
packs containing weekend take- home doses (1- 2 doses/week) will be provided on either 
Friday or Saturday. Blister packs will be collected at each research visit.  
Subjects (enrolled in the community health center) will be offered mDOT 7 times a week 
via a smartphone application, miDOT. Alternatively, mDOT will occur 3 times a week at 
the community health center observed by the clinic /research staff.   If the mDOT is 
administered at the community health center, dosing logs  will be maintained by staff . If 
receiving miDOT (virtual DOT), subjects will be seen once a week in the clinic and 
receive one observed dose each week –  observed by both clinic /research staff and the 
miDOT application. Subjects will be provided with 7-day blister packs for all of their 
doses .  
Pill counts will also be performed by counting remaining doses in blister packs. Self -
reported adherence w ill be measured using a single- item visual analogue scale (VAS) 
which has been shown to correlate well with both pill counts and virological outcomes in 
HIV-infected patients taking HAART [105, 106] . 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
30 
 8 Study Schedule  
 
Participants will be followed for up to 180 weeks: Up to 8  weeks  (±4 weeks)  of pre-
treatment evaluation, 12 weeks of treatment, 12 weeks of follow -up to determine 
SVR12, and 144  weeks of follow -up post SVR12 to determine long -term SVR and 
reinfection.  
 
8.1 Screening and Enrollment  
 
8.1.1 Screening  
Potential participants will be identified through two possible means:  chart 
review s of existing patients at the clinics  and by community -based outreach and 
screening.   Eligible participants should be enrolled within one month of 
screening.  If enrollment does not occur within one month, eligibility should be reassessed.  
 8.1.1.a.  Screening with Chart Reviews  
Prior to conducting chart reviews of existing patients at the OTP  and 
community clinics, sites will obtain a Waiver of HIPAA authorization for screening/recruitment purposes . Once this waiver is obtained, charts of 
potential participants will be reviewed to determine if the patient is eligible for participation.    
 
• The following will be reviewed  through Chart Review Part 1 : 
• HCV Antibody (ever) 
• HCV viral load  (ever) 
• HCV genotype/subtype (ever) 
• AST/ ALT and plat elets in the past 12  months (for  FIB-4  
fibrosis  estimation ),  
• Imaging if available to rule out hepatocellular carcinoma if 
the participant has advance cirrhosis/fibrosis (abdominal 
ultrasound/CT scan with contrast, or MRI with contrast)  
• Confirm that the person has not previously received DAAs  
• Document Study eligibility on CRF  
If subject is deemed eligible via “Chart Review Part 1”, then “Eligibility 
Screener” should be conducted.  
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
31 
 8.1.1.b.   Community -Based Screening  
Participants may also be recruited through c ommunity -based outreach and 
screening .  Potential participants will be identified through a n eligibility  
screening tool.  If they meet basic eligibility criteria –  e.g. HCV positive, 
recent injection drug use –  determine if they are currently seeing a provider.   
• If they have a n HCV provider:  
• Get a release of information to contact the provider  
• Obtain clinical records from the provider  
• Extract data to assess eligibility (same as listed in 8.1.1.a) , 
documenting on Chart Review Part 1.  
• Document Study eligibility on CRF  
 
• If they do not have an  HCV provider:  
• Refer to a n HCV  provider at the community health center  or 
OTP 
• Get a release of information  
• Once the clinical record has been started, extract data to 
assess eligibility as listed in 8.1.1. a, documenting on 
Chart Review Part 1.  
• Document Study eligibility on CRF  
 
8.1.2 Visit 0:  Eligibility  confirmation, Consent and Enrollment  Visit  
A research assistant will meet with the potential participant in a private room in OTP , 
community health center , or other research location to confirm  eligibility  and obtain 
consent .  Depending upon the time the participant has available and their state, this 
visit may be combined with Baseline Visit.  
 
• Discuss study procedures, risks and benefits of study participation  
• Obtain written signed consent for :  
1) Clinical trial participation;  
2) Study staff to use protected health information from clinic 
records;  
3) Study staff to disclose protected health information in event of 
clinical need  
4) staff to track any hospitalizations or emergency events  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
32 
 • Administer the sociodemographic instrument.  
• Participant will be randomized to the DOT or PN arm  (stratified, 
blocked) generated by DCC at UNM HSC.  Wait until after baseline 
assessments have been completed before revealing randomization status to the participant.  
• If the Baseline Visit is not taking place at this time, schedule the Baseline 
Visit within two  week s of enrollment.  
• Treatment initiation should begin within twelve weeks of enrollment  
 
8.2 Visit 1: Baseline Visit  
The baseline visit should occur within two weeks of enrollment  and prior to 
treatment initiation.  This  visit will assess for several different factors including 
HCV clinical factors, potential mediating  variables based on the information-
motivation -behavioral ( IMB) model, potential moderators, and additional 
psychosocial factors hypothesized to predict adherence, using the following research assistant administered instruments , in this order : 
 
• Modified ASI –  Baseline (assess drug use)  
• Behavior risk assessment (assesses injection behaviors)  
• AUDIT -C (assess alcohol use)  
• Substance Use Treatment (assess past and present experience with 
treatment)  
• PHQ -9 (assess depression)  
• GAD -7 (assess anxiety)  
• EQ-5D with added pain question (assess quality of life)  
• Stigma scale  
• Shame scale  
• Health efficacy  
• Medical Outcomes Social Support Scale  
 
The baseline visit will also include specimen collection:  
• Urine for POC drug screening  
• Collect 20 mL of whole blood in EDTA tubes for archiving.   
 
Additional services will be provided:  
• Counseling on avoidance of HCV  transmission  and HIV infection will be 
conducted.  
• Information on drug treatment and needle exchange programs will be provided , and other referrals as needed.  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
33 
  
At this visit, after all baseline instruments have been administered, research staff will 
inform the participant about their randomly assigned treatment delivery arm.  
8.3 Treatment Initiation 
Treatment initiation will occur after the baseline visit, within 12 weeks of enrollment, 
and as determined by the clinician.  Prior to initiating treatment, the clinician must 
complete the provider checklist.  
 
If treatment initiation does not begin within 12 weeks of enrollment, the participant will be withdrawn from the study.  
8.4 Chart Review Part 2  
Chart Review Part 2 should be completed at 12 weeks after enrollment regardless of if the participant initiates treatment.  The following information should be collected:  
• Pregnancy status  
• Total bilirubin  
• Albumin  
• Prothrombin time  
• HBV status  
• HAV status  
• Fibrosure, Fibroscan, liver biopsy (if available)  
• Problem list diagnoses:  
 Cirrhosis  
 Psychiatric  
 Medical  
• Imaging if advanced fibrosis/cir rhosis to rule out  hepatocellular 
carcinoma (abdominal ultrasound/CT  scan with contrast, or MRI with 
contrast)  
• Reason why patient did not initiate treatment  (if applicable)  
• HCV Viral load  
• HCV Genotype/subtype  
• FIB-4 score  
• Child -Pugh score  
• ALT and AST levels  
• Platelets  
• HIV status   
• HIV Viral load (if applicable)  
• HIV CD4 count (if applicable)  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
34 
  
 
8.5 Treatment (follow- up) visits:  
During treatment participants will have research visits and either mDOT visits or PN 
visits.  Research visits will be the same for all participants, regardless of assigned treatment arm.   Participants will be contacted by research staff regarding their first 
treatment visit by phone or in person and briefed on the visit and what to expect.  
 8.5.1  Treatment Research Visits  
 
8.5.1.a  Visit 2 : week 4 of treatment , ± 7 days 
Research staff will assess for factors of interest by administering the following questionnaires:  
 
• Modified ASI –  Follow- up (assess drug use)  
• Behavior risk assessment (assesses injection behaviors)  
• Substance Use Treatment (assess past and present experience 
with treatment)  
• Visual Analogue Scale  (assess adherence)  
 Review medical chart and record the following information:  
• HCV viremia  
• Child-Pugh score to assess  hepatic decompensation (if available)  
• HIV viral lo ad and CD4 count (if applicable)  
• FIB-4 score  (if available)  
 
Collect the following specimens:  
• Urine for POC drug screening  
 
Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.5.1.b  Visit 3 : week 8 of treatment , ± 7 days  
Research staff will assess for factors of interest by administering the following 
questionnaires:  
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
35 
 • Modified ASI –  follow- up (assess drug use)  
• Substance Use Treatment (assess past and present experience 
with treatment)  
• Visual Analogue Scale  (assess adherence)  
 
Review medical chart and record the following information:  
• HCV viremia  
• Child-Pugh score to assess  hepatic decompensation (if available)  
• HIV viral load and CD4 count (if applicable)  
• FIB-4 score  (if available)  
 
Collect the following specimens:  
• Urine for POC drug screening  
 
Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.5.1.c  Visit 4: week 12 of treatment , ± 7 days  
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Modified ASI –  follow- up (assesses drug use)  
• Behavior risk assessment (assesses injection behaviors)  
• AUDIT -C (assesses for alcohol use)  
• Substance Use Treatment (assess past and present experience with 
treatment)  
• PHQ -9 (assesses for depression)  
• GAD -7 (assesses for anxiety)  
• EQ-5D with added pain question (assesses quality of life)  
• Health efficacy  
• Medical Outcomes Social Support Scale (assesses social support)  
• Visual Analogue Scale  (assess adherence)  
• ONLY FOR THOSE IN PN ARM:  Brief Revised Working Alliance Inventory  (assesses rapport with PN)  
 
Review medical chart and record the following information:  
• HCV viremia  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
36 
 • Child-Pugh score to assess  hepatic decompensation (if available)  
• HIV viral load and CD4 count (if applicable)  
• FIB-4 score  (if available)  
 
Collect the following specimens:  
• Urine for POC drug screening  
 
Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6 Post -treatment (follow -up) visits  
Follow- up visits are scheduled in reference to the treatment start date.  
 
8.6.1 Visit 5:  week 24, ±14 days  
 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Modified socio- demographic survey ( assess for any changes in 
housing, income)  
• Modified ASI –  follow- up (assesses for drug use)  
• Behavioral risk questionnaire (assesses injection behaviors)  
• AUDIT -C (assesses alcohol use)  
• Substance Use Treatment (assess past and present experience 
with treatment)  
• PHQ -9 (assesses for depression)  
• GAD -7 (assesses for anxiety)  
• EQ-5D with added pain question (assesses quality of life)  
 
Review medical chart and record the following information:  
• HCV viremia  
• FIB-4 score  (if available)  
 
Collect the following samples:  
• Urine for POC drug screening  
• Collect 20 mL of whole blood in EDTA tubes to send to Quest 
Diagnostics for HCV viremia testing and for archiving.   
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
37 
 Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6.2 Visit 6: week 36, ± 14 days 
 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk assessment (assesses injection behaviors)  
• Shame scale (assesses shame)  
 
Collect the following samples:  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.   
 
Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.46.3 Visit 7: week 48 , ± 14 days 
 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk  assessment (assesses injection behaviors)   
• AUDIT -C (assesses alcohol use)  
• Substance Use Treatment (assess past and present experience 
with treatment)  
• PHQ -9 (assesses for depression)  
• GAD -7 (assesses for anxiety)  
• EQ-5D with added pain question (assesses quality of life)  
• Medical Outcomes Social Support Scale (assesses social support)  
 
Collect the following samples:  
• Urine for POC drug screening  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.   
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
38 
 Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6.4 Visit 8: week 60 , ± 14 days 
 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk  assessment (assesses injection behaviors)   
 
Collect the following samples:  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.  
 
Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6.5 Visit 9: week 72 , ± 14 days 
 
Research staff will assess for factors of interest by administering the following questionnaires:  
• Modified socio- demographic survey ( assess for any changes in 
housing, income)  
• Modified ASI –  follow- up (assesses drug use)  
• Behavioral risk questionnaire (assesses injection behaviors)  
• AUDIT -C (assesses alcohol use)  
 
Collect the following samples:  
• Urine for POC drug screening  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
39 
 8.6.6 Visit 10: week 84 , ± 14 days 
 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk  assessment (assesses injection behaviors)   
 
Collect the following samples:  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 
Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6.7 Visit 11: week 96 , ± 14 days 
 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk  assessment (assesses injection behaviors)   
• AUDIT -C (assesses alcohol use)  
 
Collect the following samples:  
• Urine for POC drug screening  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 
Provide the following services:  
• Counseling on avoidance of HCV transmission and HIV infection  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6.8 Visit 12: week 108, ± 14 days  
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk  assessment (assesses injection behaviors)   
 
Collect the following samples:  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
40 
 • Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 
Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6.9 Visit 13: week 120, ± 14 days  
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Modified socio- demographic survey ( assess for any changes in 
housing, income)  
• Modified ASI –  follow- up (assesses for drug use)  
• Behavioral risk questionnaire (assesses injection behaviors)  
• AUDIT -C (assesses alcohol use)  
• Substance Use Treatment (assess past and present experience 
with treatment)  
• PHQ -9 (assesses for depression)  
• GAD -7 (assesses for anxiety)  
• EQ-5D with added pain question (assesses quality of life)  
• Shame Scale (assesses for shame associated with HCV infection)  
• Medical Outcomes Social Support Scale (assesses for social support)  
 Collect the following samples:  
• Urine for POC drug screening  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
The original HERO protocol involved a total of 13 research visits over a 30- month 
period. On May 2019,  participants were offered the opportunity to participate in an 
extended follow -up period involving 4 additional research visits over a 12- month period. 
Participants were invited to participate in the protocol extension period (12 months) . 
Participants were informed of all the procedures in the additional 4 visits. Only 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
41 
 participants who agreed to participate and signed the informed consent were enrolled in 
the additional visits.  
 8.6.10 Visit 1 4: week 132, ± 14 days 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk  assessment (assesses injection behaviors)   
 
Collect the following samples:  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
8.46.11 Visit 1 5: week 1 44, ± 14 days 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk  assessment (assesses injection behaviors)   
• AUDIT -C (assesses alcohol use)  
 
Collect the following samples:  
• Urine for POC drug screening  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 
Provide the following services:  
• Counseling on avoidance of HCV transmission and HIV infection  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6.12  Visit 1 6: week 156, ± 14 days 
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Behavioral risk  assessment (assesses injection behaviors)   
 
Collect the following samples:  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
42 
 • Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 
Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
8.6.13  Visit 1 7: week 168, ± 14 days  (Exit interview)  
Research staff will assess for factors of interest by administering the following 
questionnaires:  
• Modified socio- demographic survey ( assess for any changes in 
housing, income)  
• Modified ASI –  follow- up (assesses for drug use)  
• Behavioral risk questionnaire (assesses injection behaviors)  
• AUDIT -C (assesses alcohol use)  
• Substance Use Treatment (assess past and present experience 
with treatment)  
• PHQ -9 (assesses for depression)  
• GAD -7 (assesses for anxiety)  
• EQ-5D with added pain question (assesses quality of life)  
• Shame Scale (assesses for shame associated with HCV infection)  
• Medical Outcomes Social Support Scale (assesses for social support)  
 Collect the following samples:  
• Urine for POC drug screening  
• Collect 20 mL of whole blood in EDTA tubes  to send to Quest 
Diagnostics for HCV viremia testing and for archiving.    
 Provide the following services:  
• Counseling on avoidance of HC V transmission and HIV infection.  
• Information on drug treatment and needle ex change programs , and 
other referrals as needed  
 
Research staff will thank the participant for participating in the study.  
 
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
43 
 8.7 Unscheduled Visits  
Unscheduled visits may occur at any time during the study.  They may occur for the 
following reasons:   
(1) For operational reasons, e.g., a subject may request to reschedule, or to ask 
questions;  
(2) For SAE related reasons.  When interim contacts or visits are completed in response 
to subject reports of S AEs, study staff will assess the reported event and refer the 
subject to appropriate medical care.  All SAEs will be evaluated and r eported as 
required (Section 9.4) ; 
(3) If a subject presents to the study site after having missed a scheduled visit (e.g., in 
response to locator/trac king efforts) on a day that does not fall within a scheduled 
visit window;  
(4) For other reasons at subject request.  All interim contacts and visits will be documented in subjects' study records and on applicable data collection forms. 
(5) If a subject fails HCV treatment. This visit will be solely for collection of 20 mL of 
blood  to be processed and archived by local labs for resistance testing.  
 
8.8 Patient Navigator Encounters  
Participants assigned to the P N arm will be scheduled for a minimum of 4 encounters  
with the PN, 3 of which must be conducted in- person and 1 o f which can be conducted 
either in- person or remotely (via phone, e- mail or text) . These four minimum encounters 
include: 1)  Enrollment, Assessment and Referrals ; 2) Treatment Readiness (in- person) ; 
3) Treatment Adherence Check -in (remotely via text, call or e- mail) ; and 4) After 
Treatment (in- person).  Additional c ontacts  may occur more frequently  and via different 
methods (e.g.: phone calls , texts ) depending upon the needs of the participant.  PN 
contacts  are described in more depth in the PN Protocol.   
 
8.7.1 Initial Visit  (Required)  
The initial visit will take place prior to the participant beginning treatment.  
• The PN will use the Health Promotion Guide modules I and II to 
complete the first page of the Patient Navigation Form (Sections: 
Intake, Self -Reported History, Assessment and Referrals)  
• Based on the outcome of the Assessment, t he PN and participant will 
develop a Patient Navigation Care Plan together.  
• Referrals for supportive services will be provided  
• Additional visits to complete the assessments, referrals and health promotion may be conducted as needed (optional).  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
44 
  
8.7.2  Treatment Readiness Encounter  (Required)  
In the treatment readiness encounter, the PN and participant will develop a treatment plan for the participant , incorporating input from the provider , 
including the provider in the encounter if possible.  
Using Health Promotion Guide Module III: 
• The PN will provide treatment readiness  information and counseling  
• The PN and participant will discuss the frequency and method of PN encounters to support adherence through the course of treatment. Frequency may change during treatment depending on the needs of the participant (for example, if the participant has unexpected side effects, or trouble remembering to take medications as prescribed, 
adherence support could be increased).  
• The PN and participant will complete the Treatment Planning Form , 
after receiving input from the provider . 
 
8.7.3  Treatment Adherence Encounter  (3 days post treatment initiation  - 
Required)   
The PN  is required to contact the participant  three days (2 -5 days is 
acceptable) after he/she starts treatment to address any side effects the 
patient may be experiencing, ask if any doses have been missed,  and 
intervene to improve adherence.   This encounter can occur in- person or could 
be a remote encounter (phone, email, text) depending upon participant need.  
• Based on the outcome of this check -in, the PN will update the 
Treatment Planning form with any changes to the treatment adherence 
support frequency and method, and then contact the patient as agreed 
upon for the duration of the treatment.  
• The method and frequency of treatment adherence support can be 
adjusted as needed through the course of treatment.  
 8.7.4  Treatment Period Encounters ( Weeks 1 -11) (Recommended)  
Weekly adherence check -ins during the course of treatment are 
recommended. These check -ins could occur in- person or remotely via phone 
call, text or email. If weekly contact is not appropriate for the participant, the treatment adherence encounters should occur at the frequency agreed upon 
by the provider, PN and participant and documented in the Treatment Plan . 
• The treatment adherence encounters should be documented using the 
Care Coordination Log  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
45 
 • The PN will provide referrals to services in which the participant is 
interested.  
 
8.7.5  After Treatment Encounter  (Week 12 of treatment)  (Required)  
At the final required encounter after treatment, the PN will use the Health 
Promotion Guide Module IV to:  
• Ensure the patient is aware of future clinical monitoring requirements . 
• Provide reinfection prevention information, resources and support.  
• Discharge or transition patient to an appropriate supportive program, provide referrals  
• The P N has an option  to work with the participant after treatment to 
support reinfection prevention, for up to six months (optional).  
 
8.9 mDOT Visits  
 OTP:  Participants assigned to the mDOT arm in the OTP  will have a minimum of 5 
observed doses per week by clinic or research staff.    Each observed dose will be 
recorded on the dose log, then entered into the study database.   
 Community Health Center :  Participants as signed to the mDOT arm in the C HC will 
have one observed dose by clinic or research staff per week when they pick up their medication.  Other doses will be observied  as described in section 6.1.2.  All observed 
doses will be recorded on the mDOT log (Adherence Calendar)  and entered into the 
study database.
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
46 
 9 Safety Reporting and Safety Assessment Monitoring  
9.1 Data  and Safety  Monitoring  Plan.  
The PI (Dr. Litwin) will be responsible for monitoring the safety and efficacy of this 
study, executing the Data and Safety Monitoring (DSM) plan, and complying with the reporting requirements. The PI will provide a summary of the DSM report to PCORI on 
an annual basis as part of the progress report. The DSM report will include the 
participants’ sociodemographic characteristics , a summary of S evere Adverse Events 
(SAEs) , any actions or changes with respect to the protocol,  and any quality assurance 
or regulatory issues that occurred during the past year.  The DSM report to PCORI will 
also include, when available, the results of any efficacy data analysis conducted.  
9.2 Data monitoring  plan 
Because the intervention is very low risk and is highly integrated within usual clinical care, the main element of the monitoring plan will be continuous, close monitoring by study staff and investigators, with prompt identification and reporting of adverse events  
(AEs) .  
9.3 Data Confidentiality  
Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH E6, Section 4.9 and regulatory and institutional 
requirements for the protection of confidentiality of subjects.  Forms for use as source 
documents will be derived from the electronic case report forms ( eCRFs ) and be 
provided by the Statistical and Data Coordinating Center (SDCC).  Source documents will only be accessible by study staff and all research records will be kept in a locked 
filed cabinet in the research office of the PI.  
 
Medical records are stored in locked rooms in each clinic, or in password protected 
computer files. The RA with assistance from the Co- I/PI will review the charts. Prior to 
starting the chart review process, research staff will complete online training in patient -
oriented research, including confidentiality, and will receive further training in confidentiality and the chart review protocol from the PI.  
9.4 Serious Adverse Events  
An adverse event will be considered serious when the outcome is:  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
47 
 • Death  
• Life-threatening  
• Hospitalization (initial or prolonged)  
• Disability or permanent damage  
• Congenital Anomaly/Birth Defect  
• Required intervention to prevent permanent impairment or damage 
(devices)  
• Other serious important medical event  
SAEs will be systematically assessed at each of the research visits. Any SAE will be 
reported according to the IRB requirements of the institution that the participant is 
enrolled through.  The  initial SAE report will be followed by submission of a 
completed SAE report to Einstein. In the event that a research subject either 
withdraws from the study or the investigator decides to discontinue a patient due to a SAE, the patient will be monitored by the investigator via ongoing status assessment 
until: (1) a resolution is reached, i.e., the problem requiring hospitalization has 
resolved or stabilized with no further changes expected, (2) the SAE is determined to be clearly unrelated to the study intervention, or  (3) the SAE results in death.  
Outcome of SAEs will be periodically reported to PCORI.  A summary of the SAEs 
that occurred during the previous year will be included in the annual progress report.  Subjects enrolled in this study will be prescribed FDA -approved antiviral medications 
as part of standard clinical care.  The study involves randomization to the mode of administration of the antiviral medications. For each SAE,  the site investigator  will 
determine if the SAE was related to the study.  A second opinion will obtained if 
needed from a PI at a different clinical site.  
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
48 
 10 Stakeholder Engagement  
This project was conceptualized and designed with the active participation of patients, 
researchers and other stakeholders from its inception.  Patient engagement, including 
individuals who have or are currently injecting and have HCV, or have been cured from HCV, has been actively fostered in study planning at each local site. Because this 
project brings together patients and providers representing a diverse geography and 
policy, patients and other stakeholders will continue to be actively and formally involved 
in the planning, design and execution of the study at two levels –  locally and nationally.  
At the local level, each research site will form a Local Stakeholder Advisory Board (LSAB)  which consists of a Primary Investigator, 1- 3 patients (termed Co- Investigators) 
and local representatives from participating venues such as OTPs, community health 
centers, syringe exchange programs, community -based organizations (C BOs), public 
health boards/departments, HCV providers, and homeless programs.  Site  PIs, in 
consultation with OTP  and community treatment site leadership have identified patients 
to serve on the local Stakeholder Advisory Board.  
The LSAB will meet on  a quarterly basis to allow discussion of study implementation, 
recruitment, participant tracking, intervention delivery, and outcome assessment. The board will provide technical assistance and guidance to the research sites.  
 At the second level, a National Stakeholder Advisory Board (NSAB)  will be convened, 
consisting of the local site PI and a local representative as well as representatives from national partners such as CDC (lead governmental organization); professional policy, 
educational, and advocacy organizations -  TAG, NATAP, HRC, Hepatitis Support and 
Mentor Group, Project Inform, Hepatitis Education Project, NVHR; professional patient organizations - NAMA and Medication- Assisted Recovery Services (MARS); 
governmental organizations - NYSDOHMH and NYCDOH; industry –  Gilead, Quest, 
Monogram, and Orasure. Other partners will be recruited,  such as Medicaid payers 
based on recommendations elicited in the  initial convocation of the group. The National 
Stakeholder Advisory Board will meet on a quarterly basis in Year 1 to review the project design, ensure the project will answer questions in alignment with stakeholder priorities, and provide guidance on dissemination planning from the outset. In years 2- 4 
the NSAB will meet on a quarterly basis to monitor progress to date, address difficulties with study implementation, recruitment, intervention or outcome assessment, and discuss strategies for communicating results to the wider community and all interested stakeholder groups. In Year 5 the NSAB will meet quarterly to review results and guide dissemination activities.  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
49 
 11 Statistical Considerations  
11.1 Independent Parallel Analysis 
To assure reproducibility of statistical analysis results, two independent statisticians, Dr. 
Herbert Davis at UNM and Dr. Moonseong Heo at Einstein, will adhere as closely as possible to the analytical plans detailed below. They will analyze the primary outcome, 
the 12- week sustained viral response (SVR), independently in a blinded and parallel 
manner, and compare their results. If their results are substantially different beyond a 
tolerable variation, then the two statisticians will examine each other’s analytic strategy and software codes to reach a consensus. Final results will be produced upon agreement of the two statisticians. Investigators will not be involved in this process, and 
more importantly, data analysis will not be guided or influenced by the indications of 
results. Each aspect of data analysis such as cleaning, analysis, and output will be logged and archived for review. Whenever possible, the two statisticians will follow the procedure for other outcome analysis (see 11.3 below) as well.  
11.2 Definition of Study Subjects  
The study subjects for the primary and secondary outcomes are who: 1) meet the inclusion and exclusion criteria (sections 5.1 and 5.2); 2) sign the consent form; 3) are randomized; and 4) initiate treatments, i.e., intake at least one dose of the medicine. As 
we do not anticipate that all randomized subjects will initiate treatments, a randomized 
subject will not necessarily be a study subject for primary analysis and beyond. However, depending on secondary or other study questions such as comparison of treatment initiations, all randomized subjects will serve as an analytic sample.      
11.3  Study Hypotheses  
SVR:  Among subjects who initiate HCV treatment, rate of SVR will be higher in the 
mDOT vs. PN arm. We hypothesize that SVR rate will be 80% in PN arm.  
Treatment initiation rate :  A  higher proportion of patients in the PN arm will initiate 
treatment compared to the mDOT arm, which is expected to have 60% treatment 
initiation rate.   
 
Adherence rate:   Patients in the m DOT  arm will have higher adherence rate, 
compared to the PN arm which is expected to have 80% adherence rate.  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
50 
 Treatment completion rate :  Patients in the mDOT arm will have higher treatment 
completion rate, compared to the PN arm, which is expected to have 80% completion 
rate.  
 
Detectable resistance:   Patients in the PN arm will have higher resistance rate, 
compared to the mDOT arm.  We hypothesize that the majority (65%) of patients who 
fail to achieve SVR will develop detectable resistance, yielding an overall 10% resistance rate.  
 
Reinfection rate:  The hypothesis is that there will be a minimum 5% reinfection rate 
based on meta- analysis of reinfection rates in patients treated with IFN -based 
regimens.   
11.4  Sample Size Determination 
Sample size N=300 per arm, or a total of N=600, was determined based on feasibility 
of recruitment from all sites during the study period.  Power analysis for each hypothesis below is conservatively conducted based on a reduced sample size (N= 
270 per arm, or N=540 in total) after considering 10% attrition rates. The target power 
is 80% with a two -sided significance level of 0.05. To this end, minimally detectable 
effect sizes and widths of 95% confidence intervals were computed with those parameters and the sample size after attrition.  
11.5 Primary Analytic  Principle  
The intention- to-treat principle will be used as the primary analytic principle, which 
pertains more to a real -world situation. That is, once a treatment was randomly 
assigned to a participant, the participant’s treatment identity will not change in the 
analysis even if s/he changes to the other model of care during the trial period or did 
not take the assigned treatment. Other analytic strategies such as per protocol or as -
treated analyses will also be applied to examine robustness of effectiveness of mDOT 
vs. PN.  
11.6  Preliminary  Data Analysis  
First, the  distributions of all variables will be examined using graphical or descriptive 
statistics to identify any values out of range. When identified, out of range values  will 
be found in the original record , compared and corrected if needed. Second, although 
by the stratified randomization design, each arm will equally be distributed across city, clinical site ( OTP and CHC) and stage of liver disease (cirrhosis vs. no cirrhosis), the 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
51 
 success of randomization will be checked as a way of checking key assumptions by 
comparing the PN and mDOT groups on key variables, such as age, gender, ethnicity, 
race, viral load, subtype, psychiatric history, drug use type, and social support. Continuous variables will be compared between arms using the t -tests or Mann -
Whitney tests, and categorical variables will be compared using chi -square or Fisher’s 
exact tests.  
 
Variables that are not equally distributed, albeit expected to be rare, will be included in 
multivariate models to control for their potential cofounding effects. When necessary, normal assumptions  will be checked for continuous variables by applying a formal 
Kolmogorov -Smirnov test, and if violated, Box -Cox transformations  will be considered.  
All preliminary statistical analysis and beyond will be conducted using SAS v9.3.  
11.7 Missing  data analysis  
In order to not compromise internal or external validity of our study results, every effort 
will be made to minimize missing data that could occur due to missed visits or subject 
attrition.  A maximum 10% subject attrition rate is anticipated during the first 24- week 
intervention period considering a real -world situation that withstands a tight control. 
However, the missing outcome data rates will depend on the outcome definition 
whereas most analyses will use baseline characteristics as covariates that will thus 
have negligible missing data rate.  
 The primary analysis will be based on available data without missing data imputation; 
however, we will conduct variety of missing data imputation methods for sensitivity 
analyses. Depending on the clinical nature of outcome, worst scenario imputation or, if 
deemed more relevant, mean imputation methods will be considered. In addition, fully specific conditional specification multiple imputation methods will also be applied, which are applicable to non- ignorable missing data.  
 Characteristics of patients who are lost to follow -up will be compared to those that 
remain in the study to assess the degree of any selection bias due to attrition, and the analysis results of the different types of imputed missing data will be compared to the primary analysis results.  In particular, variability of the coefficients of primary 
predictors across the different imputation methods will be assessed to evaluate 
robustness of the findings.  If the changes in the coefficients are greater than 15% from those of the primary analysis, we will limit the generalizability, internal and external 
validity of our findings, which we nevertheless do not believe will occur if attrition rates 
are less than 25%.  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
52 
 11.8 Heterogeneity of mDOT  or PN effects 
The mDOT or PN effects depending on outcome (see Aim 1 hypotheses) will be 
assessed for each subgroup stratified various factors (e.g., clinic setting, demographic, 
or clinical), which are specified below, and will be compared across the subgroup 
strata. Forest plots will be produced to show graphically the differences or contrasts in effect sizes across all subgroups. Formal tests will follow via testing significance of 
pertinent interaction terms with the mDOT or PN arm indicator in statistical models.  
11.9  Mediated mDOT  or PN effects  
Mediator analysis will be conducted to identify potential mediators between mDOT/PN 
effect and each of the five outcomes. A mediator will be a variable whose value changes or occurs between the baseline and the end of the study; for example, 
reduced stigma and shame, extent of peer support, changes in social support, and increased self -efficacy. The potential mediating effects will be assessed by differences 
in mDOT or PN effect sizes depending on outcome between with and without a 
potential mediator variable in statistical models. Their significance will be tested following the Baron and Kenny mediation test principle.  
11.10   Analytic plan for Primary and Secondary outcomes : SVR, 
Treatment initiation rate, Adherence rate, and Treatment completion rate  
 Study Hypotheses:  
SVR:  Among subjects who initiate HCV treatment, rate of SVR will be higher 
in the m DOT vs. PN arm. We hypothesize that SVR rate will be 80% in PN 
arm. 
Treatment initiation rate:  A  higher proportion of patients in the PN arm will 
initiate treatment compared to the mDOT arm, which is expected to have 
60% treatment initiation rate.   
 
Adherence rate:  Patients in the mDOT arm will have higher adherence rate, 
compared to the PN arm which is expected to have 80% adherence rate.  
Treatment completion rate .  P atients in the mDOT  arm will have higher 
treatment completion rate, compared to the PN arm, which is expected to 
have 80% completion rate.  
Statistical Model  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
53 
 Multivariable logistic regressions will be applied to test the overall effectiveness of 
mDOT or PN on the five binary outcomes (success vs. failure) with the SVR rate as the 
primary outcome. The arm indicator will be the predictor for each outcome. With respect to adherence outcome in particular, repeatedly measured adherence will be analyzed (using 6 post -baseline time points and adherence as a continuous measure) applying a 
mixed effects linear model to test if the two arms are significantly different. This model 
accounts for within- subject longitudinal outcome correlation by taking the subject -level 
intercept as random. All models will include potential confounding variables that are 
significantly different between the two arms; the sites will be included as a covariate as well. Likewise, mixed effects logistic regression will also be applied to test the 
significance of PN and DOT on repeatedly -measured undetectable HCV VL throughout 
the intervention period, adjusting for substance use in addition to other confounding 
variables. Changes in illicit drug use will be analyzed using urine toxicology data from each visit, counting the “person- month” as a unit of analysis, and analyzing the 
percentage of person- months that are positive for use of illicit drugs during the study 
period using a t -test or Mann- Whitney test.  
Power analysis: Minimally detectable effect sizes 
SVR:   Considering the base 80% SVR rate of in PN arm, a minimum of 9% difference 
between the two arms will be detected (i.e., 89% vs. 80%, O dds Ratio (OR) =2.1) in a 
multivariable logistic regression model in which confounding variables will explain 10% of variation in the predictor variable. This study posits that a >9% difference in SVR between the PN and mDOT groups will be clinically significant based on studies that 
showed that SVR in treatment naive patients was >90% [14] . 
Mixed effects logistic regression models for the undetectable HCV load will be able to detect even smaller percent point difference since they will utilize repeated measures for each subject no matter how large within- subject  outcome correlations  will be. 
Treatment initiation rate:  With anticipated 60% treatment initiation rate in the mDOT 
arm, a minimum of 7 % difference will be detectable (i.e., 60% vs. 67 %, OR=0.74) in any 
outcome in a multivariable logistic regression model in which confounding variables will explain 10% of variation in the predictor variable.   Note that sample size for this analysis 
will be N=1000, the total number of randomized participants.  
 
Adherence rate:  With expected 80% adherence rate in the PN arm, a minimum of 9% 
difference in adherence rates between the 2 arms will be detectable (i.e., 89% vs. 80%, OR=2.1) in a multivariable logistic regression model.  Per the repeatedly measured continuous adherence percentage outcome, mixed effects linear models will be able to 
detect standardized effect sizes (mean difference divided by a pooled S tandard 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
54 
 Deviation (SD)) greater than 0.2 irrespective of magnitudes of within -subject outcome 
correlations overt time. In a previous DOT study, a standardized effect size of mDOT vs. 
TAU was estimated to be 0.6.   
Treatment completion rate .  Under the expected 80% completion rate in the PN arm, 
a minimum of 9% difference in completion rates between the two arms will be 
detectable (i.e., 89% ( mDOT) vs. 80% (PN), OR=2.1). 
 Subgroup Heterogeneity Analyses  
 
To assess heterogeneity of mDOT or PN effects, additional analyses will be conducted 
to evaluate whether the m DOT effect varies by variety of subgroups stratified by the 
following characteristics: OTP  (50%) vs. C HC (50%); Males (70%) vs. Females (30%); 
Patients using illicit drugs during treatment (65%) vs. those not using illicit drugs (35%); 
HIV/HCV coinfected (28%) vs. HCV mono -infected (72%); Cirrhosis (21%) vs. non-
cirrhosis (79%); African American / Latino (41%) vs. Caucasian (59%); Marginally housed (26%) vs. stably housed (74%); Comorbid mental illness (55%) vs. no mental 
illness (45%); and Peer -support (70%) vs. no peer -support (30%). Initially, subgroups 
will be defined based on the above factors and estimates of treatment effect will be 
obtained separately in each subgroup using the methods described above.  The significance of any heterogeneous m DOT or PN effects across these factors will be 
formally tested by testing significance of corresponding interaction terms with the mDOT or PN arm indicator.  In addition, we will also conduct within- arm subgroup 
analyses to identify factors that are associated with outcomes within arms.  For example, one test would be if increased social support will be associated with higher 
treatment initiation within the PN arm.  
 
Power analysis for subgroup analysis: For the subgroup analysis, the minimally 
detectable effect size will depend on the sample size of subgroups. However, assuming 
that a subgroup has 50% of the total sample, i.e., N=270, and that a base outcome rate 
is 80% (e.g., SVR), then ≥ 12% difference will be detected using a Chi -square test. The 
minimally detectable standardized effect size for continuous outcome will be 0.3. This 
power analysis also applies to detect binary or continuous factors associated with outcome from within -arm subgroups analyses since the sample size of each arm will be 
N=270 after attritions. For the subgroups with smaller sample size, the minimally detectable effects sizes, binary or continuous, will be larger. For example, for some of our subgroups will be as small as 20% (or, N= 108) of the sample (e.g. HIV/HCV coinfected), minimum effect sizes are larger at ≥17% for SVR and 0.5 standardized 
effect size for continuous variables.  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
55 
 11.11   Analytic plan  for Resistance and Reinfection Rates   
 
Study Hypotheses:  
Detectable resistance:  Patients in the PN arm will have higher resistance rate, 
compared to the mDOT  arm.  We hypothesize that the majority (65%) of patients who 
fail to achieve SVR will develop detectable resistance, yielding an overall 10% 
resistance rate.  
 
Reinfection rate:  The hypothesis is that there will be a minimum 5% reinfection rate 
based on meta- analysis of reinfection rates in patients treated with IFN -based 
regimens.   
 
Statistical Model  
 The precision of proportion of participants who develop resistance or reinfection will be 
determined with 95% confidence intervals (CIs) calculated using exact binomial methods. To identify factors associated with resistance or reinfection, we will conduct bivariate analysis using (exact) logistic regressions for both continuous and dummy -
coded categorical variables. A series of bivariate analyses will be followed by a 
multivariable logistic regression that includes all factors significant in the bivariate 
analysis at a two- sided 0.05 significance level. All analyses will be separately 
conduced for each of resistance and reinfection outcomes.  For the examination of association between resistance and adherence in particular, a multivariable logistic 
regression will also be applied in which overall adherence will be the primary predictor 
in the presence of other factors identified in the bivariate logistic regression analysis. In all multivariable analysis, the mDOT arm indicator will be included for adjusting 
purpose.  
 
Power  analysis   
With a total of N=540 after attrition, the expected 95% confidence intervals are (7.7%, 
12.8%) and (3.5% and 7.2%) for the resistance and reinfection rates, respectively, For the bivariate analysis, any binary variable with odds -ratio (OR) ≥ 1.8 (or 7% vs. 14.4%) 
for resistance and OR > 3.3 (or 2.5% vs. 7.8%) for reinfection will be identified with >80% power; and any continuous variable with OR>1.6 and OR>2.1 per 1 SD unit 
changes will be detected for resistance and reinfection, respectively. In the multivariable 
analysis, binary variables with OR > 2.5 (7% vs. 16.2%) and OR > 4.0 (2.5% vs. 9.3%) and continuous variables with OR  1.8 and OR>2.5 per 1 SD unit change will be 
detected for resistance and reinfection, respectively, with>80% power, expecting that as 
large as 30% of variation of each variable will be explained by the other variables in the 
models for aim 2 analyses. Likewise, for detecting association between a continuous 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
56 
 adherence rate and resistance, OR  ≥1.8 per 1 SD unit change will be detected with > 
80% power.  
11.12    Analytic plan for Aim 3 
11.12.1  Patient  Navigator  (PN) Stakeholder  Qualitative Study.   
Recruitment . 10-15 PNs will be recruited in Year 1 including at least one navigator from 
each site. Data will be utilized as part of a formative evaluation, with the goal of 
identifying emerging barriers to program success and facilitating problem solving [107] .  
Data collection. After participating in an informed consent process, navigators from each of the project sites will be interviewed by telephone. Study staff have considerable 
experience with telephone interviews [108, 109] . Thirty -minute  semi -structured 
interviews will be conducted focusing on navigator experiences and perceptions of the 
intervention, with particular focus on gaining the perspectives of these front line workers into barriers to successful patient outcomes.  
Analysis. Interviews will be recorded and transcribed. Data will be analyzed using Miller 
and Crabtree’s “Editing” approach [110] . The Qualitative Team (Drs. Karasz, McKee, 
and RA) will create a preliminary coding scheme, which is then revised in iterative 
fashion as it is applied to new subsets of the data. When the coding scheme is judged to be adequate by the team, the entire data set will be coded in NVivo , a qualitative data 
analysis program that facilitates the rapid organization and retrieval of thematically related data [109, 111, 112] . Themes related to successes and failures, and sources of 
stress and satisfaction will be summarized. Data summaries will be presented to the NSAB to discuss implications, identify emerging problems, and brainstorm solutions.  
 
11.12.2  The Patient Stakeholder Qualitative Study.  
The focus of the Patient Stakeholder Study, conducted in Years 2- 5, will be to 
understand barriers to successful outcomes along the pathway to care, including: the lack of treatment uptake, poor adherence (< 80%), failure to achieve SVR, development 
of drug resistance, and HCV reinfection. By contrast to the Navigator study, the Patient 
Stakeholder Study incorporates a comparative design. With the goal of identifying barriers to successful treatment, structured comparisons will be made between  
successful and unsuccessful patients at each stage along the pathway to care.  
 Recruitment. At the treatment uptake stage, a sample of 10 patients who successfully 
initiated treatment  will be recruited and interviewed, and a similar group of patients who 
did not. Similarly,  we will recruit patients who adhered/did not adhere, achieved SVR/did 
not adhere; and who became re- infected/remained HCV free.  
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
57 
  
Data Collection . Patients will be recruited and interviewed by telephone. An interview 
guide will be developed that focuses on potential barriers and facilitators to successful treatment participation, including perceptions of the intervention, perceived need for 
treatment, relationships with staff, and experiences with medication. The guide will 
include questions on contextual barriers to successful participation such as economic, social, and psychological stressors, as well as facilitators such as social support and other resources.  
 Data Analysis. Data analysis will proceed in two steps. The first step entails the standard data analysis approach described above. In a second step, the analysis team will make structured comparisons across successful and unsuccessful patients, searching for patterns in the data that reveal core differences across groups and 
provide insight into why some patients are able to succeed with treatment and some are 
not.  In Year 2, data from these comparative analyses will be summarized and presented to the Stakeholder team, with the goal of improving the capacity of intervention team to provide patient -centered care and better meet patient needs. Data 
collected in later years of the project will be used as part of a summative evaluation, to understand the successes and failures of the intervention with the goal of increasing 
scientific knowledge and improving the effectiveness of future interventions.  
 11.12.3  Quantitative Analysis  
The proposed mDOT and PN interventions are guided by Fisher’s IMB model [113- 115]. 
The IMB model asserts that information, motivation, and behavioral skills are 
fundamental determinants of adherence [113] . The IMB model further specifies that 
personal and situational characteristics, such as poor psychologic health, substance use, unstable housing, or inadequate access to medical care, may moderate these 
relationships and impact adherence [113] . In extreme cases, strong negative effects on 
adherence are expected, and interventions aimed at improving information and motivation may not be effective without adjuvant support. Both interventions - mDOT 
and PN - focus on enhancing information, motivation, and behavioral skills, and provide 
adjuvant support to lessen negative impacts of moderating factors. While primarily operating on behavioral skills, the mDOT intervention also enhances both information and motivation (through support from nurses and outreach workers).  The PN 
intervention addresses information (through education), motivation (through PN and 
peer support), and behavioral skills (PN and peer -led skill- building sessions).  
 
IMB model mediator analysis. The analysis  will examine if mDOT  vs. PN adherence, for 
example, will be mediated by IMB components. Specifically, IMB model mediators of 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
58 
 adherence will be assessed at baseline, and during the intervention, and will use as the 
observed values of IMB mediators changes in those variables from the baseline to the 
intervention period. The indirect effects of IMB mediators will be tested by assessing 
changes in coefficients of the intervention effect (PN or m DOT) with and without IMB 
component(s) in mixed effects models. Confidence intervals of the mediated effects will be calculated by bootstrapping, and mediation assumed if confidence intervals do not 
include zero.
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
59 
 12 Data Handling /Record Keeping/Source Documents  
The principal investigator at each site is responsible for ensuring the accuracy, 
completeness, legibility, and timeliness of the data reported.  
 Forms for use as source documents will be derived from the electronic case report forms (eCRFs) and provided by the SDCC to the sites to record and maintain data for 
each subject enrolled in the study.  All source documents should be completed in a 
neat, legible manner to ensure accurate interpretation of data.  Black or blue ink is required to ensure clarity of reproduced copies.  When making a change or correction, the original entry should be crossed out with a single line, and the change should be 
initialed and dated.  Do not erase, overwrite, or use correction fluid or tape on the 
original.   Data entry, media/tools and data management platform are describe d in detail  
in a Data Management Plan.  
 
Data reported in the eCRF should be consistent with the source documents or the 
discrepancies should be documented.  
12.1  Source Documents and Access to Source Documents  
 
Each participating site will maintain appropriate medical and research records for this 
trial, in compliance with ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality of subjects.  Forms for use as source documents will be derived from the eCRFs and be provided by the Statistical and Data 
Coordinating Center (SDCC).  Source documents will only be accessible by study staff 
and all research records will be kept in a locked filed cabinet in the research office of the PI. 
 
These  medical  records  are stored  in locked  rooms  in each  clinic,  or in password  
protected  computer  files. The RA with assistance  from the Co-I/PI will review  the charts.  
Prior  to starting  the chart  review process,  research  staff will complete online  training  in 
patient -oriented  research,  including  confidentiality,  and will receive  further  training  in 
confidentiality  and the chart  review protocol  from the PI. 
12.2  Data Management Responsibilities  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site principal investigator.  During the study, the investigator must 
maintain complete and accurate documentation for the study.  All source documents 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
60 
 and laboratory reports must be reviewed by the clinical team and data entry staff, who 
will ensure that they are accurate and complete.  Serious adverse events must be 
reviewed by the site principal investigator or designee.   
 The Biostatistics group at the UNM Division of Epidemiology, Biostatistics and Preventive Medicine will serve as the Statistical and Data Coordinating Center  (SDCC)  
for this study, and will be responsible for data management, quality review, analysis, and reporti ng of the study data.  
12.3  Data Capture Methods  
Sources of data will include: blood and urine tests, participant interviews, medical 
charts, direct observation of staff  and PNs , and electronic adherence monitors.  
Information from participant interviews will be either directly entered into an electronic 
data capture system, or will be recorded on paper, then entered.  In- person research 
interview data will be recorded on paper or computer -based data collection instruments.  
All HCV VL load, HCV resistance assays, urine tests, and adherence data will be measured by electronic monitors.   
12.4  Types of Data  
This study will collect quantitative and qualitative information.  Quantit ative data will be 
collected from 1) subject interviews; 2) blood specimens for HCV viral load and resistance assays; 3) urine toxicology test at each research visit; 4) electronic monitors for assessing adherence; 5) clinic records for methadone or buprenorphine  dose, 
clinical tests  and medical history.  Qualitative  data will be collected from patients and 
staff interviews (qualitative aim).  
12.5  Timing/Reports  
• Each site will enter accrual  and study data from source forms into the study 
database maintained by the SDCC within 7 days of collection.  
• The UNM SDCC will provide weekly accrual, and enrollment  reports by site and 
overall. Reports will include information on treatment initiation, study exiting and 
loss to follow up.   
• The UNM SDCC will maintain a “Consort” log of trial progress.   
12.6 Study Records Retention 
The UNM SDCC will store and secure all quantitative data. The Research Informatics 
Core of the Montefiore Medical Center will store all qualitative data. A patient -level de-
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
61 
 identified copy of the final datasets will be available in electronic form for investigators 
willing to sign a data use agreement with provisions for protecting patients from any 
attempts to de -identify the data, as well as that any findings derived from the data would 
be made public within nine months of the end of the final funding year or by earlier 
request, to PCORI and other relevant parties. Documentation will accompany the final data sets that enables others in the research community to utilize the data for 
additional/secondary analysis. Data may be shared electronically or via file- transfer 
protocols and will be provided in a SAS or STATA datafile for quantitative data, and 
original transcriptions for qualitative data obtained through interviews and focus groups. Syntax files from SAS or STATA used for quantitative analyses will be archived and can 
also be made available.  
The link between the subject and the research study will be destroyed 5 years  after the 
end of the study.   
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
62 
 13 Quality Assurance 
There will be three levels of data quality assurance:  
First, at ea ch site there will be trained research staff (either the project director or 
research associate)  who will be responsible for complete and accurate data collection 
and entry of source data into the UNM DCU. The designated research staff  at each 
hub will undergo training in all aspects of the clinical protocol, with refresher training 
once per year.  
Secondly, the UNM SDCC will have a central data quality coordinator who will: (1) 
provide training for site -based personnel; (2) perform periodic monitoring and audits of 
the data collected including source (clinical records and laboratory) and entered (site-
based) to ensure consistent and accurate records.  
Third, the UNM SDCC will have a data manager who will be responsible for receiving, 
reviewing and cleaning all of the study data. The data manager will be responsible for 
regular collation of all incoming data from study sites, maintenance of recruitment, 
enrollment and accrual records, generation of weekly accrual reports, and conducting 
basic analyses for reports and papers. S/he will ensure secure data storage of verified and documented data, audit trails for data changes, and ensure back -up systems are 
working.  
PROCESS AND FIDELITY ASSESSMENT: All patient navigators and outreach 
workers will be trained by the New York City Department of Health and Mental Hygiene (NYC DOHMH), and NYC DOHMH will provide technical assistance to project directors and other staff during the study period. To assess fidelity, local 
Project Directors will observe local project staff to ensure that patient navigation 
protocols are appropriately delivered.  Feedback will be provided with retraining and reassessment when indicated.  In addition, Montefiore site visit protocols will include observation of local staff delivering patient navigation and DOT protocols.  
 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
63 
 14 Ethics/Protection of Human Subjects  
14.1  Ethical Standard/Declaration of Helsinki  
The investigator(s) will ensure that this study is conducted in full conformity with 
principles of the Belmont Report:  Ethical Principles and Guidelines for the Protection of Human Subjects of Research of the National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research (April 18, 1979) and codified in 45 
CFR 46, 21 CFR 50 and 56, and ICH E6; 62 Federal Regulations 25691 ( 1997), if 
applicable. The investigator’s Institution will hold a current Federal -wide Assurance 
(FWA) issued by the Office for H uman Research Protections (OHRP)  for federally 
funded research.  
14.2  Institutional Review Board 
Each participating institution will provide for the review and approval of th e study  
protocol and the associated informed consent documents, by an appropriate ethics review committee or Institutional Review Board (IRB) listed on their Federal Wide 
Assurance.  Any amendments to the protocol or informed consent materials must also 
be approved before they are placed into use unless change is for the safety of the subject.  Only those IRB members who are independent of the investigators and the sponsor should provide an opinion on study related matters.  Verification of IRB 
approval of the protocol and the written informed consent will be transmitted by the 
investigator or designee prior to the shipment of medication.  No deviations from or 
changes to the protocol will be initiated without prior approval of an appropriate amendment unless change is for the safety of the subject.  
14.3  Informed Consent Process  
The written informed consent document will embody the elements of informed consent as described in the Declaration of Helsinki and will adhere to the ICH Harmonised Tripartite Guideline for Good Clinical Practice.  Informed consent should be 
implemented before any protocol -specified procedures or interventions are carried out.  
Informed consent will be obtained in accordance with 21 CFR 50.25 and 45 CFR 46.  
Information should be presented both orally and in written form.  
 Prior to the administration of any study measures, research assistants will obtain consent for screening using an informed consent form (ICF) , which describes the study, 
and reinforces the confidentiality of all survey information. Interested patients who are 
eligible for the study after an initial pre-screen will sign and date a written informed 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
64 
 consent document. The informed consent process will include discussion of the study 
purpose; study interventions, study procedures, research visit schedule and 
reimbursement; risks, benefits, and alternatives to study participation; and confidentiality 
of research records. The following general principles will be emphasized:  
• Participation is voluntary  
• Participants can discontinue participation at any time  
• Emergency contact information will be provided  
• They are required to consent for trial participation  
• We will require authorization for study staff to use protected health information, including laboratory test results from OTP  and CHC records , and 
HCV provider  
• In the event of psychiatric distress, study staff will require authorization to 
disclose health information to medical staff  
• Treatment related visits will occur through usual systems of delivery of care, and 
thus may be billed to insurance as any other medical visit.  
• There is the possibility that the participant will not receive HCV treatment  
• There is also possibility that additional medications (ribavirin) may be 
recommended/added during treatment, which will not be provided by the study  
• There is the potential for direct benefit if the participant receives HCV treatment, as there is a 95% chance that they will be cured based on current clinical trial 
evidence  
• The subject is free to ask questions at any time to allow him or her to understand the purpose of the study and the procedures involved  
• Refusal to participate involves no penalty or loss of medical benefits  
 The aims of the study and all tests to be carried out will be explained.  The subject will be given the opportunity to ask about details of the trial, and will then have time to 
consider whether or not to participate.  If they do decide to participate, they will sign and 
date two copies of the ICF, one for them to take away and keep, and one to be kept by the investigator.  These forms will also be signed and dated by the study staff person obtaining the informed consent.  
 Study staff must inform subjects that the trial involves research, and explain the purpose of the trial, those aspects of the trial that are experimental, any expected benefits, all 
possible risks (including a statement that if the participant in the study receives HCV 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
65 
 treatment, the particular treatment or procedure may involve risks to the subject or to 
the embryo or fetus, if the subject is or may become pregnant, that are currently 
unforeseeable), the expected duration of the subject’s participation in the trial, the 
procedures of the research study, including all invasive procedures, and the probability for random assignment to treatment groups.  Subjects will be informed that they will be notified in a timely manner if information becomes available that may be relevant to their 
willingness to continue participation in the trial.  They must also be informed of 
alternative procedures that may be available, and the important potential benefits and risks of these available alternative procedures.  Subjects must receive an explanation as to whether any compensation and any medical treatments are available if injury 
occurs, and, if so, what they consist of, or where further information may be obtained.  
Subjects must be informed of the anticipated financial expenses, if any, to the subject for participating in the trial, as well as any anticipated prorated payments, if any, to the subject for participating in the trial.  They must be informed of whom to contact (e.g., the 
investigator) for answers to any questions relating to the research project.  Information 
will also include the foreseeable circumstances and/or reasons under which the subject’s participation in the trial may be terminated.  The subjects must be informed that participation is voluntary and that they are free to withdraw from the study for any reason at any time without penalty or loss of benefits to which the subject is otherwise 
entitled.  
 
Neither the investigator, nor the trial staff, should coerce or unduly influence a subject to 
participate or continue to participate in the trial.  The extent of the confidentiality of the 
subjects’ records must be defined, and subjects must be informed that applicable data 
protection legislation will be followed.  Subjects must be informed that the auditors(s), IRB, and regulatory authority(ies) will be granted direct access to the subject’s original medical records for verification of clinical trial procedures and/or data without violating 
the confidentiality of the subject, to the extent permitted by the applicable laws and 
regulations, and that, by signing a written ICF, the subject is authorizing such access.  Subjects must be informed that records identifying the subject will be kept confidential, and, to the extent permitted by the applicable laws and/or regulations, will not be made 
publicly available and, if the results of the trial are published, the subject’s identity will 
remain confidential.  
 Informed consent forms must be in a language fully comprehensible to the prospective 
subjects.  Informed consent shall be documented by the use of a written ICF approved 
by the IRB and signed and dated by the subject and the person who conducted the informed consent discussion.  The signature confirms that the consent is based on information that has been provided and all questions have been answered to the 
prospective subject’s satisfaction.  Each subject’s signed ICF must be kept on file by the 
Q4 Protocol_PCORI   Version 4 .0 
  21 MAY2019  
   
66 
 investigator for possible inspection by Regulatory Authorities and/or the sponsor and 
Regulatory Compliance persons.  The subject should receive a copy of the signed and 
dated written ICF and any other written information provided to the subjects, and should 
receive copies of any signed and dated ICF updates and any amendments to the written information provided to subjects.  
14.4  Subject Confidentiality  
Drug abuse and HCV infection require special sensitivity to issues of confidentiality. Patient confidentiality will be carefully protected. Study records will be kept in locked files and/or within limited access, code- protected computer files, available only to the 
investigators and study personnel. Patient identifiers will be removed and only initials 
and code numbers will be present on study records and documents.   
Protection of subject identity . Subjects will not be identified by name on any written 
or verbal reports. They will only be identified by a study ID number. Subjects’ names 
and study ID numbers will be kept in a password protected fil e in the research office 
of the Principal Investigator. Access will only be allowed to the senior project staff. The link between the subject and the research study will be destroyed 5 years  after 
the end of the study.  All research records will be kept in a secure area and locked in a file cabinet in the research office of the PI.  
Protection of confidentiality  
To ensure that confidentiality is maintained, the following procedures  will be 
instituted : 
• Medical staff will not have access to trial survey data, except under specific circumstances.   Specifically, report of active suicidal ideation will trigger 
immediate clinical evaluation by an on- site physician, physician assistant, or 
psychiatrist, based on the psychiatric distress protocol. Consents will be obtained from participants for disclosure of research information under these circumstances prior to their enrollment in the proposed trial.  
• The Research Assistant will complete the Collaborative Institutional Training Initiative (CITI)  computer -based training program, which includes 
a specific module on issues of privacy and confidentiality.  
• A system will be used that prevents linking sensitive material to participants’ 
personal identifiers. All documents with participant identifiers, including 
consent forms, medical records and contact information, will be filed together. All documents that do not include identifying information or signatures will use participants’ study IDs rather than names and will be filed 
Q4 Protocol_PCORI   Version 4.0 
  21 MAY2019  
   
67 
 together. All forms will contain either participants’ names or their study IDs, 
but not both. Data collection forms will include no identifiers other than a 
study ID code. There will only be one electronic document that links 
participants’ names to their study IDs, which will be password protected.  
• Study records will be stored on a password protected computer database and/or in locked file cabinets.  
• A federal Certificate of Confidentiality will be obtained by each site to protect 
participants’ sensitive information.  
• Phone messages left for participants to schedule research visits will not include personal identifying information or mention HCV or OAT  
• Publication or presentation of study results will not identify subjects by name.  
 
68 
 15  Protocol Conduct  
The protocol will be conducted in compliance with federal regulations and the principles 
of Good Clinical Practice (GCP), including the following processes:  
• Protocol registration, activation, and implementation;  
• Informed consent, screening, and enrollment;  
• Clinical and safety assessments;  
• Safety monitoring and reporting;  
• Data collection and documentation;  
• Study follow -up and close- out; 
• Quality management;  
• Protocol monitoring and compliance;  
• Risk reduction counseling; and  
• Specimen collection, processing, and analysis.  
15.1 Record  Confidentiality  
 
The investigators will maintain appropriate medical and research records for this trial, in compliance with ICH E6 GCP and regulatory and institutional requirements for the 
protection of confidentiality of subjects.  The study protocol, documentation, data and 
all other information generated will be held in strict confidence.  No information concerning the study,  or the data will be released to any unauthorized third party, 
without prior written approval of the sponsor.  The principal investigators from each site 
will obtain a Certificate of Confidentiality from NIH to further protect subjects’ privacy.  
15.2  Data Collection, Handling, Source Documents  
Clinical research data will be collected as described in detail in Section 12.  
 Standard GCP will be followed to ensure accurate, reliable, and consistent data 
collection.  Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH, GCP, regulatory, and institutional requirements for the protection of confidentiality of subjects.  
 
69 
 15.3  Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical 
Practice (GCP), or Manual of Procedures  (MOP) requirements.  The noncompliance 
may be on the part of the subject, the investigator, or the study site staff.  As a result of 
deviations, corrective actions are to be developed by the site and implemented promptly.   
 
These practices are consistent with Good Clinical Practice:  
4.5  Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
5.1  Quality Assurance and Quality Control, section 5.1.1  
5.20 Noncompliance, sections 5.20.1 and 5.20.2d  
 
It is the responsibility of the site to use continuous vigilance to identify and report deviations  per site IRB guidelines.    
 
All deviations from the protocol must be addressed in study source document s.  A 
completed copy of the Protocol Deviation (PD) Form must be maintained in the 
Regulatory File.  Protocol deviations must be submitted to the local IRB/IEC per their 
guidelines.  The site PI/study staff is responsible for knowing and adhering to their IRB 
requirements.  
15.4  Recruitment and Retention of Study Subjects  
The research staff  will recruit potential participants from OTPs and community health 
centers and by referral from other community -based organizations. Recruitment will be 
active (medical providers and community outreach workers will inform HCV -infected 
patients about the study) and passive (clinic counseling staff, word of mouth, and fliers 
in clinic waiting areas).  For active recruitment medical providers and community outreach workers will inform HCV -infected patients about the study and assist with 
referral, and for passive recruitment subjects will self -refer.  Self -referred subjects will   
meet with their provider to determine whether starting HCV treatment is appropriate.   
Potential study participants will demographically and clinically reflect those most impacted by chronic hepatitis C and will be identified in a number of ways: community outreach including posters and written materials at recruitment sites and at other key 
locations in the community; by self -referral; by referral from local patient stakeholders 
such needle exchange programs; by referral from staff at OAT  treatment centers, 
participating clinics or other medical or mental health caregivers; and by direct approach 
from a site Research Assistant / Patient Navigator (RA/PN).    
 
70 
 Retention will be enhanced using multiple methods including but not restricted to:  1) 
conducting interviews with participants at research visits;  2) reminders using text 
messaging (SMS), written reminders and phone calls ; and 3) reimbursement for 
research assessments.   
To assist retention, at enrollment and subsequent visits, the following information will 
be collected: 1) participants’ address, phone number, and social security number  (if 
available and required by local sites) ; 2) contact information of family or friends; 3) 
contact information of participants’ community -based organizations; 4) contact 
information of case managers;  5) locations where participants “hang out” ; and 6) 
participants' social media presence and willingness to be contacted by person- to-
person messaging on this medium . 
15.5  Study Subject Reimbursement  
Participants will receive $20 for each of 1 7 research visits ($20/visit, 17 research visits, 
$340 total)  and an additional $5 for returning one-week electronic blister packs  or $10 
for two -week (12 weeks , $5/week , $60 total)  for a total of $ 400 per participant. This 
level of reimbursement is standard for clinical research conducted in our setting, and is 
not considered undue inducement for research participation.  
  
 
   
 
  
 
71 
 16  Publication Policy 
 
The project is designed based on the dissemination priorities and needs for the sites, 
patients and stakeholders involved in its planning and implementation.  During the 
project period, patient partners and other stakeholders will have an active role in 
developing appropriate material and communicating and disseminating information 
about the project and its activities and reporting to their various constituencies about progress made towards meeting the goals and objectives of the study. Project staff will work with each to ensure that customized material is produced to ensure that 
communication is understandable and usable by each constituency. Patient partners 
will be involved in outreach to the local community through both the participating sites in each city and local media as well as through other community connections to PWID in neighboring cities to make other patients aware of study opportunities to receive 
treatment for HCV. As progress is made in generating findings, patient and stakeholder 
partners will be invited to author or co- author articles and opinion pieces describing the 
study findings for publication in local press and other media outlets. Other advocacy and public health stakeholders will facilitate disseminating study findings based on the 
communities and organizations they represent. This will be accomplished by sharing 
study findings to their membership and to their funders through newsletters, website postings, presentations at meetings and conferences, as well as through more formal professional publications.  The study has a publication policy and procedure document.   
  
 
 
72 
 17  References  
1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM , et 
al. Chronic hepatitis C virus infection in the United States, National Health and 
Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014, 160:293-300. 
2. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu -Weinberger C. Meta- regression of 
hepatitis C virus infection in relation to time since onset of illicit drug injection: the 
influence of time and place. Am J Epidemiol 2008, 168:1099- 1109.  
3. Hepatitis C Kills More Americans than Any Other Infectious Disease. In; 2016.  
4. Lansky A, Finlayson T, Johnson C, Holtzman D, Wejnert C, Mitsch A , et al. 
Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014, 9:e97596.  
5. Centers for Disease C, Prevention. Vital signs: evaluation of hepatitis C virus 
infection testing and reporting -  eight U.S. sites, 2005- 2011. MMWR Morb Mortal 
Wkly Rep 2013, 62:357- 361. 
6. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A , et al.  
Emerging epidemic of hepatitis C virus infections among young nonurban 
persons who inject drugs in the United States, 2006- 2012. Clin Infect Dis 
2014, 59:1411- 1419.  
7. Hepatitis C Virus Prevention in Young Persons who Inject Drugs. In: US Department of Health and Human Services (HHS) Office of HIV/AIDS and Infectious Disease Policy; 2013.  
8. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV -related chronic disease. Centers for Disease Control and Prevention. 
MMWR Recomm Rep 1998, 47:1-39. 
9. Weiss U. Hepatitis C. Nature 2005, 436:929.  
10. Brown RS. Hepatitis C and liver transplantation. Nature 2005, 436:973-978. 
11. Wasley A, Grytdal S, Gallagher K, Centers for Disease C, Prevention. Surveillance for acute viral hepatitis --United States, 2006. MMWR Surveill Summ 
2008, 57:1-24. 
12. Aspinall E CS, Doyle J, et al. Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis 2013, 57:S80-S89. 
13. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta -analysis. Clin Infect Dis 2013, 56:806-816. 
14. AASLD/IDSA/IAS- USA. Recommendations for testing, managing, and treating 
hepatitis C. In.  
15. Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A , et al.  
Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013, 57 Suppl 2 :S129- 137. 
16. Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence- based 
interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy 2015, 26:922-935. 
17. Bruggmann P LA. Clin Infect Dis 2013, 57:S56 -S61. 
 
73 
 18. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD , et al. 
Hepatitis C virus treatment for prevention among people who inject drugs: 
Modeling treatment scale- up in the age of direct -acting antivirals. Hepatology 
2013, 58:1598- 1609.  
19. Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV -mono -infected and 
HIV/HCV -co-infected injection drug users. AIDS 2005, 19 Suppl 3 :S179- 189. 
20. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis 2013, 207 Suppl 
1:S19-25. 
21. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD , et al.  
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006, 20:2361- 2369.  
22. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D , et al. 
Limited uptake of hepatitis C treatment among injection drug users. J Community 
Health 2008, 33:126-133. 
23. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G , et al. 
Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008, 93:141-147. 
24. Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G. Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment. AIDS Patient 
Care STDS 2009, 23:993-999. 
25. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with 
assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev 2012, 31:918- 924. 
26. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I , et al.  A 
global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013, 57:1325- 1332.  
27. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S , et al. Barriers to and 
facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010, 24:753-762. 
28. Tran T MT, Thuluvath P, et al. Safety and efficacy of treatment with sofosbuvir + GS-5816 +/ - ribavirin for 8 or 12 weeks in treatment -naïve patients with genotype 
1-6 HCV infection. In: AASLD . Boston, MA; 2014.  
29. Kofman A, Litwin A, Swan T, al e. Short Communication:  Heterogeneity in Drug and Alcohol use- Related Exclusion Criteria in Direct Acting Antiviral Agent 
Hepatitis C Treatment Trials for Individuals Coinfected with Hepatitis C Virus and HIV. Clin Res HIV/AIDS 2015, 2:1. 
30. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis 
C: is it worth it? Hepatology 2014, 59:1246- 1249.  
31. Medicaid.gov. Medicaid Drug Rebate Program. In; 2014.  
32. Foundation KF. State Health Facts, Medicaid Income Eligibility Limits for Adults 
as a Percent of the Federal Poverty Level. In; 2015.  
 
74 
 33. Office of the Assistant Secretary for Planning and Evaluation USDoHaHS. 
Poverty Guidelines. In; 2015.  
34. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med 2015, 163:215- 223. 
35. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ , et 
al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug 
user populations. Hepatology 2012, 55:49 -57. 
36. Wyles D. Antiviral Resistance and HCV Therapy. JOD 2013, 207:S33.  
37. Wyles D MA, Cheng W, et al. Long- term persistence of HCV NS5A variants after 
treatment with NS5A inhibitor ledipasvir. In: EASL . Vienna, Austria; 2015.  
38. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014, 20:2902-
2912.  
39. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M , et al. Reinfection 
with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 2010, 25:1281- 1284.  
40. Grady BP, Vanhommerig JW, Schinkel J, Weegink CJ, Bruisten SM, Lindenburg CE, et al. Low incidence of reinfection with the hepatitis C virus following 
treatment in active drug users in Amsterdam. Eur J Gastroenterol Hepatol 2012, 24:1302- 1307.  
41. Midgard H ea. Incidence of hepatitis C reinfection following SVR –  a seven year 
follow- up of Scandinavian patients infected through injecting drug use. In: EASL . 
Vienna, Austria; 2015.  
42. Hill A. Effects of SVR on the risk of liver transplant, hepatocellular carcinoma, 
death and reinfection: meta- analysis of 129 studies in 34,563 patients with 
hepatitis C infection. In: AASLD . Boston, MA; 2014.  
43. Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A , et al.  Frequent 
longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis 2013, 56:405-413. 
44. Sacks- Davis R GJ, Osborn MK, Dore GJ, Cox A, Rice T, et al. HCV reinfection 
and spontaneous clearance after spontaneous clearance of primary HCV infection: the InC3 Study. In: Symposium . Melbourne, Australia; 2013.  
45. Vickerman P, Grebely J, Dore GJ, Sacks- Davis R, Page K, Thomas DL, et al. 
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 2012, 205:1342- 1350.  
46. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC , et al. Spontaneous 
control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138:315-324. 
47. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S , et al. Protection against 
persistence of hepatitis C. Lancet 2002, 359:1478- 1483.  
48. Shiffman ML. A balancing view: We cannot do it alone. Am J Gastroenterol 2007, 102:1841 -1843.  
49. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 2010, 65:1327 -1329.  
 
75 
 50. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N 
Engl J Med 2001, 345:215- 217. 
51. Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis 2013, 57 Suppl 
2:S51-55. 
52. Edlin BR ea. Is it justifiable to withhold treatment for hepatitis C from illicit -drug 
users? N Engl J Med 2001, 345:211-215. 
53. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D , et al. Outcomes 
of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011, 364:2199- 2207.  
54. Jack K, Willott S, Manners J, Varnam MA, Thomson BJ. Clinical trial: a primary -
care-based model for the delivery of anti -viral treatment to injecting drug users 
infected with hepatitis C. Aliment Pharmacol Ther 2009, 29:38 -45. 
55. Newman AI, Beckstead S, Beking D, Finch S, Knorr T, Lynch C , et al. Treatment 
of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre. Can J Gastroenterol 2013, 27:217- 223. 
56. Southern WN, Drainoni ML, Smith BD, Christiansen CL, McKee D, Gifford AL, et al. Hepatitis C testing practices and prevalence in a high- risk urban ambulatory 
care setting. J Viral Hepat 2011, 18:474-481. 
57. McGinn T, O'Connor -Moore N, Alfandre D, Gardenier D, Wisnivesky J. Validation 
of a hepatitis C screening tool in primary care. Arch Intern Med 2008, 168:2009-
2013.  
58. Federally Qualified Health Centers, Centers for Medicare and Medicaid. In.  
59. SAMSHA. Results from the 2008 National Survey on Drug Use and Health: 
National Findings. In: Substance Abuse and Mental Health Services Agency; 2009.  
60. Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real -world substance abuse 
treatment outcomes. Drug Alcohol Depend 2013, 131:127- 135. 
61. Tempalski B, Cleland CM, Pouget ER, Chatterjee S, Friedman SR. Persistence of low drug treatment coverage for injection drug users in large US metropolitan areas. Subst Abuse Treat Prev Policy 2010, 5:23. 
62. Friedman SR, Tempalski B, Brady JE, Friedman JJ, Cooper HL, Flom PL , et al. 
Predictors of the degree of drug treatment coverage for injection drug users in 94 metropolitan areas in the United States of America. Int J Drug Policy 
2007, 18:475-485. 
63. Kerr T, Wood E, Grafstein E, Ishida T, Shannon K, Lai C , et al.  High rates of 
primary care and emergency department use among injection drug users in Vancouver. J Public Health (Oxf) 2005, 27:62-66. 
64. Chitwood DD, Sanchez J, Comerford M, McCoy CB. Primary preventive health 
care among injection drug users, other sustained drug users, and non- users. 
Subst Use Misuse 2001, 36:807-824. 
65. Norton BL FJ, Steinman M, Yu K, Deluca J, Cunningham CC, Litwin AH. High 
HCV cure rates for drugs users treated with DAAs at an urban primary care clinic. In: CROI . Boston, MA; 2016.  
 
76 
 66. Alavi M, Grebely J, Micallef M, Dunlop AJ, Balcomb AC, Day CA , et al. 
Assessment and treatment of hepatitis C virus infection among people who inject 
drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis 2013, 57 
Suppl 2 :S62-69. 
67. Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F , et al. Peginterferon 
plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Dig Liver Dis 2009, 41:303-307. 
68. Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC, Jr., Monto A, Rossi SJ , et 
al. Efficacy and safety of peginterferon alfa- 2a/ribavirin in methadone 
maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008, 103:2757- 2765.  
69. Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse 2012, 38:206-212. 
70. Litwin AH, Harris KA, Jr., Nahvi S, Zamor PJ, Soloway IJ, Tenore PL , et al. 
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009, 37:32-40. 
71. Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ , et al. 
Integrated internist -  addiction medicine -  hepatology model for hepatitis C 
management for individuals on methadone maintenance. J Viral Hepat 
2012, 19:47-54. 
72. McAllister G, Innes H, McLeod A, Dillon JF, Hayes PC, Fox R , et al.  Uptake of 
hepatitis C specialist services and treatment following diagnosis by dried blood 
spot in Scotland. J Clin Virol 2014, 61:359-364. 
73. Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point -of-
care and standard HCV testing in a mobile medical clinic. J Community Health 2014, 39:922-934. 
74. Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis 2013, 13:9. 
75. Grebely J GK, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007, 18:437-443. 
76. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007, 18:406-410. 
77. Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a 
methadone maintenance treatment program. J Subst Abuse Treat 2012, 43:424-
432. 
78. Crawford S, Bath N. Peer support models for people with a history of injecting 
drug use undertaking assessment and treatment for hepatitis C virus infection. Clin Infect Dis 2013, 57 Suppl 2 :S75-79. 
 
77 
 79. Roose RJ, Cockerham -Colas L, Soloway I, Batchelder A, Litwin AH. Reducing 
barriers to hepatitis C treatment among drug users: an integrated hepatitis C 
peer education and support program. J Health Care Poor Underserved 2014, 25:652-662. 
80. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001, 61:211-215. 
81. Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F , et al. 
Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV -infected injection drug users. Clin Infect Dis 2005, 40 
Suppl 5 :S304- 312. 
82. Zeremski M, Dimova RB, Zavala R, Kritz S, Lin M, Smith BD , et al.  Hepatitis C 
virus -related knowledge and willingness to receive treatment among patients on 
methadone maintenance. J Addict Med 2014, 8:249-257. 
83. Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A , et al. A 
randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health 2013, 103:e81-88. 
84. Westergaard RP, Stockman LJ, Hyland HA, Guilfoyle SM, Fangman JJ, Vergeront JM. Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale- up of Antiviral Therapy. J Prim Care Community Health 
2015, 6:215- 217. 
85. Hellard M, Sacks -Davis R, Gold J. Hepatitis C treatment for injection drug users: 
a review of the available evidence. Clin Infect Dis 2009, 49:561 -573. 
86. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone 
maintenance clinics: a randomized controlled trial. Drug Alcohol Depend 2011, 113:192-199. 
87. Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV -infected people who use drugs. Curr HIV/AIDS 
Rep 2012, 9:287-312. 
88. Flanigan TP TL, Mitty JA. Use of community -based, directly observed therapy for 
HIV infection: lessons learned for treatment of hepatitis C virus infection. Clin Infect Dis 2005, 40:S346 -348. 
89. Litwin AH, Berg KM, Li X, Hidalgo J, Arnsten JH. Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. BMC Infect Dis 2011, 11:315.  
90. Saiz de la Hoya P, Portilla J, Marco A, Garcia -Guerrero J, Faraco I, Anton J , et 
al. Directly observed therapy for chronic hepatitis C: a randomized clinical trial in 
the prison setting. Gastroenterol Hepatol 2014, 37:443-451. 
91. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus -infected injection drug users receiving directly observed therapy 
with peginterferon alpha- 2a (40KD) (PEGASYS) and once- daily ribavirin. J Subst 
Abuse Treat 2010, 38:338 -345. 
92. Nahvi S, Litwin AH, Heo M, Berg KM, Li X, Arnsten JH. Directly observed antiretroviral therapy eliminates adverse effects of active drug use on adherence. Drug Alcohol Depend 2012, 120:174-180. 
 
78 
 93. Berg KM, Litwin AH, Li X, Heo M, Arnsten JH. Lack of sustained improvement in 
adherence or viral load following a directly observed antiretroviral therapy intervention. Clin Infect Dis 2011, 53:936-943. 
94. Hart JE LC, Ivers LC, et al. Effects of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta -analysis and systematic review. J Acquir Immune Defic Syndr 2010, 54:167-
179. 
95. Mitty JA MG, Taylor L, et al. The use of community -based modified directly 
observed therapy for the treatment of HIV -infected persons. J Acquir Immune 
Defic Syndr 2005, 39:545-550. 
96. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005, 40 Suppl 5 :S339- 345. 
97. Harris KA, Jr., Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010, 4:20-26. 
98. Litwin AH LX, Moonseong H, et al. Directly observed HCV treatment in methadone clinics –  preliminary results. In: International Viral Hepatitis Meeting . 
Baltimore, MD; 2011.  
99. Bradford JB, Coleman S, Cunningham W. HIV System Navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS 2007, 21 Suppl 
1:S49-58. 
100. Ford M JA, Rude EJ. Check Hep C: A community -based approach to hepatitis C 
diagnosis in high- risk populations. In: AASLD . Boston, MA; 2014.  
101. R FCaH- M. Evaluating the quality of HCV care and treatment in primary care 
settings. In: AASLD . Washington, DC; 2013.  
102. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013, 57 
Suppl 2 :S56-61. 
103. Ramirez AG, Turner BJ. The role of peer patients in chronic disease management. Ann Intern Med 2010, 153:544-545. 
104. Leof A GM, Thielke A, et al. Sofosbuvir for the treatment of hepatitis C and evaluation of the 2014 AASLD treatment guidelines. In. Portland, OR: Center for Evidence- based Policy, Oregon Health & Science University.  
105. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B , et al.  
Self-reported adherence to antiretroviral medications among participants in HIV 
clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12:255- 266. 
106. Kalichman SC, Amaral CM, Swetzes C, Jones M, Macy R, Kalichman MO , et al. 
A simple single- item rating scale to measure medication adherence: further 
evidence for convergent validity. J Int Assoc Physicians AIDS Care (Chic) 
2009, 8:367- 374. 
107. Glasgow R. What types of evidence are most needed to advance behavioral 
medicine? . Annals of Behavioral Medicine: A Publication of the Society of 
Behavioral Medicine 2008, 35:19 -25. 
 
79 
 108. Karasz A, McKee MD, Roybal K. Women's experiences of abnormal cervical 
cytology: illness representations, care processes, and outcomes. Ann Fam Med 2003, 1:196- 202. 
109. Garcia IA, Blank AE, Eastwood EA, Karasz A. Barriers and facilitators to the implementation of SPNS interventions designed to engage and retain HIV positive women of color in medical care. AIDS Behav 2015, 19:655-665. 
110. Miller WL, Crabtree BF. Qualitative analysis: how to begin making sense. Fam Pract Res J 1994, 14:289-297. 
111. McKee MD, Karasz A, Weber CM. Health care seeking among urban minority adolescent girls: the crisis at sexual debut. Ann Fam Med 2004, 2:549-554. 
112. Karasz A. Cultural differences in conceptual models of depression. Soc Sci Med 
2005, 60:1625- 1635.  
113. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information- motivation -
behavioral skills model of adherence to antiretroviral therapy. Health Psychol 2006, 25:462-473. 
114. Amico KR, Toro -Alfonso J, Fisher JD. An empirical test of the information, 
motivation and behavioral skills model of antiretroviral therapy adherence. AIDS 
Care 2005, 17:661- 673. 
115. Starace F, Massa A, Amico KR, Fisher JD. Adherence to antiretroviral therapy: an empirical test of the information- motivation -behavioral skills model. Health 
Psychol 2006, 25:153-162. 
 
 
80 
 Appendix One: Patient Navigator Tasks  
Patients  who are HCV  Antibody -positive  (Linkage to Care)  
1) Navigate  patients  to on-site viral load testing  
2) Follow- up with all patients  for post -test counseling  
3) Attempt to contact  patients lost  to follow -up 
4) Provide basic  HCV -related  education:  natur al history,  prevention  of 
transmission,  evaluation,  and treatment  
 
Patients who have chronic  hepatitis  C (Care  Coordination:  Case  
Management,  Education,  Outreach,  Collaboration,  Logistical  Support,  and 
Other)  
1) Schedule  patients  for first HCV  evaluation with HCV  specialist  (within  one week)  
2) Schedule patients  for follow- up evaluation  and treatment  meetings  
3) Work  closely  with HCV  primary  care champion  to ensure patients  are engaged 
with HCV  care (e.g. weekly  HCV  clinic  and preparation of charts  for weekly  
visits)  
4) Promote adherence to all HCV -related appointments  
5) Schedule patients  for all off-site liver clinic  appointments  as appropriate  (e.g. 
decompensated cirrhosis ; other  liver disease;  transplant  evaluation)  
6) Remind  patients  one day prior to appointment  
7) Check  to see if patients  adhered  to appointment  
8) Check  in with patients  after seeing  HCV  primary  care champion:  
a) see how patient  is doing (build  rapport)  
b) ask patient  to clarify  next steps  
c) schedule follow- up appointments  in real-time (e.g. ultrasound)  
d) elicit fears  and concerns  
e) answer  questions  
9) Identify  barriers  and facilitators  to care and provide  motivational  interviewing 
to assist  patients  in overcoming barriers.  
10) Motivate  patients  to continue to move  through  the HCV  cascade  of care 
11) Work  with any insurance issues and refer to Medicaid office  or social  
worker  as appropriate  
12) Prior authorizations  for all HCV  medications,  adjuvant  medications  (e.g. zofran 
for nausea),  and other related- procedures  (e.g. MRI for liver imaging)  
13) Work  with Medicaid  managed  care plans  and mail order  pharmacies  for 
ordering and delivering  HCV - related medications  
14) Work  with pharmacist:  dispensing medications,  checking  in regarding 
patient  adherence to medications;  counseling with patients;  and drug-drug 
interactions  
15) Provide adherence  counseling  and assist  with side effect  management   for  
patients  on treatment  
16) Pre-treatment  readiness  assessments to identify  potential  barriers  to treatment  
17) Make  all HCV -related appointments  and ensure follow- up: 
 
81 
 a) Ultrasound  and other  imaging  
b) Liver  biopsy  if necessary  
c) Other  off-site specialists appointments  (e.g.dermatology)  
d) Upper  endoscopy  to screen for varices  
e) Transplant  evaluation  
18) Provide  HCV  education (evaluation,  treatment,  adherence,  and side effect  
management)  including  formal  brief educational  intervention  with power -
point  slides  
19) Conduct  rapid HCV  testing  at outreach  sites and navigate new HCV  antibody  
+ patients  to clinic  for follow -up viral load testing, primary  care,  and HCV -
related  care.  
20) Organize and administer  any program  incentives  (e.g. metro  cards)  
21) Collect all PN-related data and input  in timely  manner  within  databases  
22) Maintain all PN-related databases  
23) Provide weekly  updates  to HCV  team  meeting for problem  solving  and QI 
24) Attend  local HERO team meetings  
25) Report  to Project  Director  
26) Attend  national HERO PN team meetings via conference calls  
27) Work  at multiple  clinics  in various  locations  throughout  the week  
28) Work  closely with community  to develop and maintain  HCV -related networks  
(e.g. syringe  exchange  program  and CBOs)  
29) Work  with HCV  peers  
30) Obtain outside medical  records  as needed  
31) Provide administrate support  to the Project  Inspire team  
32) Send  letter  and/or  telegram  as needed for patients  lost to follow- up 
33) Work  with Montefiore/NYDOH teams for exchange of data 
34) Other  duties  as needed  
 
82 
 Appendix 2: Check Hep C Patient Navigation Program –  Workflow for Project HERO  

 
83 
 Appendix Three:  Study Visit Table  
Table 3: Study Visit Table  
  Pre-Treatment  Treatment Visits  Post -Treatment Visits 
Research Visit Activities 
Time (Minutes)  
Pre-Screening  
Enrollment  
Baseline 
Week 4, ± 1wk  
Week 8, ± 1 wk  
Week 12, ± 1 wk  
Week 24, ± 2 wks  
Week 36, ± 2 wks  
Week 48, ± 2 wks  
Week 60, ± 2 wks  
Week 72, ± 2 wks  
Week 84± 2 wks  
Week 96, ± 2 wks  
Week 108, ± 2 wks  
Week 120, ± 2 wks  
Week 1 32, ± 2 wks  
Week 1 44, ± 2 wks  
Week 1 56, ± 2 wks  
Week 1 68± 2 wks  
Visit Number      0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
TIME (in min)      40 70 37 22 90 70 20 65 15 45 15 25 15 90 15 25 15 90 
Release of Information    X X                               
Informed Consent  30   X                               
Randomization      X                               
Instruments                                      
Socio -Demographic Survey  10   X                               
Short Socio -Demographic Survey  5             X       X       X       X 
Behavioral Risk Assessment  10     X X   X X X X X X X X X X X X X X 
Depression (PHQ -9) 5     X     X X   X           X       X 
Anxiety (GAD -7) 4     X     X X   X           X       X 
AUDIT -C 3     X     X X   X   X   X   X   X   X 
Modified ASI – baseline  10     X                                 
Modified ASI – follow -up 5       X X X X       X       X       X 
Substance Use Treatment  3     X X X X X   X           X       X 
EQ-5D 8     X     X X   X           X       X 
Visual Analogue Scale 
(Adherence)  2       X X X                           
Medical Outcomes Social Support 
Scale  5     X     X     X           X    X 
 
84 
   Pre-Treatment  Treatment Visits  Post -Treatment Visits 
Research Visit Activities 
Time (Minutes)  
Pre-Screening  
Enrollment  
Baseline 
Week 4, ± 1wk  
Week 8, ± 1 wk  
Week 12, ± 1 wk  
Week 24, ± 2 wks  
Week 36, ± 2 wks  
Week 48, ± 2 wks  
Week 60, ± 2 wks  
Week 72, ± 2 wks  
Week 84± 2 wks  
Week 96, ± 2 wks  
Week 108, ± 2 wks  
Week 120, ± 2 wks  
Week 1 32, ± 2 wks  
Week 1 44, ± 2 wks  
Week 1 56, ± 2 wks  
Week 1 68± 2 wks  
Brief Revised Working Alliance  
(PN arm only)  5           X                        
Stigma Scale  5     X                              
Shame Scale  2     X         X             X    X 
Health Efficacy Scale  3     X     X                       
 
85 
   Pre-Treatment  Treatment Visits  Post -Treatment Visits 
Research Visit Activities 
Time (Minutes)  
Pre-Screening  
Enrollment  
Baseline 
Week 4, ± 1wk  
Week 8, ± 1 wk  
Week 12, ± 1 wk  
Week 24, ± 2 wks  
Week 36, ± 2 wks  
Week 48, ± 2 wks  
Week 60, ± 2 wks  
Week 72, ± 2 wks  
Week 84± 2 wks  
Week 96, ± 2 wks  
Week 108, ± 2 wks  
Week 120, ± 2 wks  
Week 1 32, ± 2 wks  
Week 1 44, ± 2 wks  
Week 1 56, ± 2 wks  
Week 1 68± 2 wks  
Labs                                      
HCV Antibody    MC   MC                             
HCV viremia    MC   MC MC MC MC MC X X X X X X X X X X X X 
HCV Genotype/subtype        MC MC                           
HIV Test        MC                             
HIV Viral Load*        MC MC MC MC                       
HIV CD4*        MC MC MC MC                       
AST/ALT/Platelets/    MC   MC MC MC MC MC                     
FIB-4 Calculation      
Total Bilirubin        MC                             
Albumin        MC                             
Prothrombin time        MC                             
FibroSure/Fibroscan/Liver biopsy        MC MC**  MC**                          
Imaging study**    MC   MC                             
Child -Pugh Score (exclude B,C)        MC MC MC MC                       
Pregnancy test*        MC                             
Archiving sample        X       X X X X X X X X X X X X X 
HCV GenoSure NS5A/NS5B 
Assay*                X                     
HBV panel        MC                             
HAV Status        MC                             
Urine toxicology POC assay        X X X X X   X   X   X   X  X  X 
MC = Medical Chart                  * If applicable   **If available  
 
86 
 Appendix Four : Implementation Study  
 
Implementation Evaluation--Protocol  
 
We are proposing to add an implementation evaluation to the approved study. We propose to examine 1) implementation ‘outcomes’ —how well the program was 
implemented across the eight study sites; and 2) causal factors affecting implementation, i.e. barriers and facilitators.  
 Implementation outcome data  that will be collected in this evaluation include: data on 
program acceptability, feasibility, dose, and fidelity. Acceptability to patients will be assessed using a single patient satisfaction question administered at the F12 interview, and through a qualitative interview with a convenience sample of approximately 40 (the number of interviews depends on data saturation, and may be as many as 60) patients. Feasibility will be assessed through examination of recruitment and retention records (assessed through study databases); and by an examination of the execution of work plans for each of the 8 study sites. Intervention ‘dose’ and fidelity will be assessed by examining the degree to which treatment plans are adhered to (collected through administrative data); and by visit logs created by patient navigators indicating the degree to which the patient received the planned elements of navigation.  
 Barriers and facilitators to implementation  will be assessed through interviews and 
questionnaires collected with key stakeholders in the study, including site leaders, site staff, and patients. We will use the following methods.   1. Site leader interviews. We will conduct between 2 and 5 telephone interviews with 
site leaders at each site over the next 5 years. Site PIs will assist the team in identifying appropriate clinical leaders. Telephone interviews are expected to last approximately 15-30 minutes and will be recorded and transcribed. Questions will focus on relevant 
topics such as clinical site research experience, current on site HepC treatment, DOT, PN, local resources, larger societal influences, perceptions of study burden and feasibility, etc. Site leaders will be approached through their local PIs and interviews will be conducted by the Bronx Qualitative Team members. In an initial phone call we will explain the purpose of the study. If participants are willing to participate they will engage in an informed oral consent by telephone. Specifics of these interviews may be found in Table 1.  
 2. Grumbach Workplace Environment Questionnaire.  This brief questionnaire 
addresses the workplace environment in primary care. It was designed to measure staff perceptions of teamwork and adaptability to take on practice improvements and innovations.  The questionnaire will also include a few questions about attitudes towards HepC tx for active PWID. The questionnaire will be administered to relevant staff of the clinical sites —including nursing, physicians, support staff, front desk, etc. Participants 
will be approached at the meeting or in their workplaces and requested to fill out these 
 
87 
 forms anonymously.  The Project Director will collect the questionnaires during site 
visits. A waiver of consent is requested for this questionnaire.  
 3. Working Alliance Questionnaire.  This questionnaire will be administered at the F12 
follow up research visit to all patients in the PN arm of the study. This questionnaire assesses the quality of the relationship between the patient and the front line treatment provider. This questionnaire will be included in the interview packet. No separate consent process will be needed.  
 4. Staff Interviews . These 10 -30 minute qualitative interviews will focus on staff 
experiences with the HERO project, levels of engagement and enthusiasm, and perceptions of structural/institutional as well as patient level barriers to program implementation. Relevant staff members will be identified through discussions with Site Principal Investigators or local Clinical Site leaders. We will conduct these interviews with identified staff (number is currently unknown, depends on the site, but may be up to 6 staff members per site, or 48 overall). In an initial phone call , we will explain the 
purpose of the study. If participants are willing to participate they will engage in an informed oral consent by telephone. These interviews will be conducted at various time points with different groups of staff. Specifics may be found in the tables.  
 5. Patient Satisfaction, Treatment Experiences and Barriers Interviews.  These 30 
minute qualitative interviews will examine patient experiences, characteristics, and perceptions associated with varied treatment outcomes. They will be administered to patients in various groups chosen for their contrast on key outcomes: patients who successfully adhere to treatment (n<=10) vs. those who do not (n<=10); patients who 
complete treatment (n<=10) vs. those who do not (n<=10); and patients who remain virus free (n<=10) vs. those who do not (n<=10) for a total of n<=60. The total number depends on data saturation achieved through the analysis: we anticipate that at least 8 patients in each group or approximately 1 per site will be recruited for a total of at least 6 per site.  A $15 incentive will be offered to participate in the phone interviews. If 
participants are willing to participate they will engage in an informed oral consent by telephone.  
  
 
88 
 TABLE I: DATA COLLECTION PLAN FOR BARRIERS/FACILITATORS STUDY  
 Pre-Implementation  
Purpose  Data Collection Instrument  Respondent’s  Responsible  
To understand 
relevant 
experiences and 
characteristics at 
HERO clinical sites that may impact 
project  roll out  Site Leader Interview s. 15-30 minute telephone 
interviews. Questions will focus on relevant topics such as site research experience, current on site 
HepC treatment, DOT, PN, local resources, 
perceptions of study burden and feasibility, etc...    Clinical site medical 
directors or other stakeholders determined 
through discussion with 
PIs  
Bronx Implementation 
Team  
 
To understand 
characteristics of 
the work environment that 
may impact 
Implementation from the point of view of clinical and admin staff  Grumbac h Workplace  Environment  
Questionnaire.  This brief questionnaire addresses 
the workplace environment in primary care. It was designed to measure staff perceptions of teamwork 
and adaptability to take on practice improvements 
and innovations.   The questionnaire will also include a few questions about attitudes towards HepC tx for active PWID.   Relevant clinical and 
administrative staff of the sites —including 
nursing, physicians, 
support staff, front desk, 
etc. To be administered during  staff meeting or in the clinic/health center  Site RAs  
Early Implementation Period (3 -6 months into project period)  
Purpose  Data Collection Instrument  Respondent’s  Responsible  
To understand 
perceptions of 
HERO among clinic 
site staff  Brief staff interview s. Open ended questions 
focusing on perceived relevance, burden, 
feasibility, and complexity of HERO will be 
conducted with relevant staff identified through 
discussions with PI or site leaders.  Relevant providers  and 
admin staff  Bronx Project 
Coordinator @ 
Site Visit  
12 Week Follow Up Patient Interviews  
Purpose  Data Collection Instrument  Respondent’s  Responsible  
To understand the quality 
of HERO staff/patient 
interactions  Working Alliance Questionnaire  
(Administered at F12 Interview)  All Patients in the PN 
Arm Site F12 Inter -
viewers  
 
 
 
89 
 Post  Implementation –Timeframe TBD  
Purpose  Data Collection Instrument  Respondents  Responsible  
To understand site 
leaders perceptions of 
the program and barriers/facilitators  Site Leader Interview s. A 20 minute telephone 
interview. Questions will focus on site leader’s perceptions of the project —barriers, facilitators, 
benefits, burden, surprises. The interview will also examine structural/environmental factors such as local politics, insurance regulatory environment, 
stigma, and similar issues potentially affecting 
sustainability and replication-- Relevant site 
leaders as described above  Bronx 
Implementation Team  
To understand frontline 
worker experiences, characteristics, and 
perceptions of 
implementation barriers and facilitators to DOT 
and PN Interventions  Frontline Worker Interviews.  This 30 minute 
qualitative interview will focus on frontline worker experiences with the HERO project, level of 
engagement and enthusiasm, and perceptions of 
structural/institutional as well as patient level barriers  to program implementation.  Frontline workers 
as many as feasible  Bronx 
Implementation Team  
To understand patient 
level barriers and facilitators to successful 
treatment from patient’s 
viewpoint and understand experiences with 
treatment  Patient  Treatment Experiences and Barriers to 
treatment  interviews. * This 30 minute qualitative 
interview will examine patient experiences, 
characteristics, and perceptions associated with 
varied treatment outcomes  Purposive 
sampling from various outcome 
groups  Bronx 
Implementation  
Team  
 
90 
 TABLE II: DATA COLLECTION PLAN FOR ASSESSING IMPLEMENTATION OUTCOMES   
Variables  Data Collection  & Source  Responsible  Method of Date Analysis  Responsible:  
Acceptability of Intervention  
Pt. Satisfaction w TX  1 TX Satisfaction Question  @ 
F12 Site RA  Quantitative  Site RA  
Positive/Negative 
Experiences with TX  Brief Treatment Experiences 
Interview @ various time points  Site RA  Structured, ‘Quantitated’ 
Thematic Analysis w/ 
Qual Data Analysis 
Program  Bronx Implementation Team  
Feasibility of Intervention  
Recruitment 
Milestones  Research Database  Site staff  Quantitative  Local/New Mexico  
Retention in 
Intervention  Research Database  Site Staff  Quantitative  Local/New Mexico  
Execution of Work 
Plans  Work Plans for Each Arm with 
Milestones and Dates 
Achieved, i Bronx Project 
Director  Qualitative  Bronx Implementation Team  
Intervention Dose  
Directly Observed TX      
# Observed Doses / 
#Planned Observed 
Doses  
 Nurse calendar/log or patient 
log--TBD  Frontline Staff  Quantitative  Local/NM  
Patient Navigation      
2 in person meetings/  
3 Follow up calls (TBD)  Case Note s or Other Records —
TBD with DOH Team  Frontline staff  Qualitative assessment 
& quant tabulation  Site Staff Supervisor  
Fidelity of PN Intervention  
To Be Discussed with DOH PN Team  
Care Plan Completed  Navigation Care Plan  Frontline staff  Qualitative assessment, 
tabulation  PN Records  
Initial Medical Evaluation 
Completed  Case Notes  Frontline staff  Qualitative assessment, 
tabulation  PN Records  
Referrals Made  Case Notes  Frontline staff  Qualitative assessment, 
tabulation  PN Records  
Referrals Followed up  Case Notes  Frontline staff  Qualitative assessment, 
tabulation  PN Records  
Education Sessions #1 & 
2 Provided  Attendance records /group, 
Case notes /ind. # minutes  Frontline staff  Tabulation  PN Records  
 
91 
 Consent  Data Collection Instrument s  
Site leader oral consent  
 • Site Leader Interview  
• Site Le ader guide post implementation  
Staff Oral Consent  
 • Brief Staff interview  
• Frontline Staff Interview Post Implementation  
Patient Oral Consent  • Brief Patient Experience Interview  
• Patient Treatment Experiences and Barriers/Facilitators to 
Treatment  
Request waiver of consent —anonymous survey on 
worksite culture  • Grumbach  Questionnaire  
Regular study consent form —to be embedded in 12 -
Week Follow up Interview  • Working Alliance Questionnaire  
 
92 
  
 
 